Author: "Arzu Yorgancioglu" / Publication Year Range: Last 10 years - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Arzu Yorgancioglu"' showing total 107 results

Start Over Author "Arzu Yorgancioglu" Publication Year Range Last 10 years

107 results on '"Arzu Yorgancioglu"'

1. Attitudes toward and exposure to gender discrimination in work life by pulmonologists and thoracic surgeons: a questionnaire-based survey among Turkish thoracic society members

Author: Birsen Ocakli, Arzu Yorgancioglu, Sinem Gungor, Fusun Topcu, Yesim Yigiter Senol, Basak Goktas, Nurdan Kokturk, Eylem Tuncay, Baran Gundogus, Hilal Altinoz, Yesim Yasin, Ipek Ozmen, Serap Duru, Elif Ozari Yildirim, Tulin Sevim, Cansel Atinkaya Ozturk, Esra Uzaslan, and the Turkish Thoracic Society Women and Lung Diseases Working Group
Subjects: gender discrimination, physicians, chest diseases, thoracic surgery, gender roles, Medicine (General), R5-920
Abstract: BackgroundThis study aimed to evaluate attitudes toward and exposure to gender discrimination in work life by chest diseases specialists and thoracic surgeons.MethodsA total of 275 members of Turkish Thoracic Society (TTS) were included on a voluntary basis in this online cross-sectional questionnaire-survey using an internal member-only social media platform of TTS. The questionnaire form elicited items on sociodemographic characteristics, occupational characteristics and gender discrimination in work life (general opinions, attitudes and exposure).ResultsFemale doctors (vs. males) were less likely to be a thoracic surgeon (13.8% vs. 34.5%, p
Published: 2024
Full Text: View/download PDF

2. Concurrent validity, cut‐offs and ability to change of patient‐reported outcome measures for rhinitis and asthma in MASK‐air®

Author: Jean Bousquet, Bernardo Sousa‐Pinto, Josep M. Anto, Anna Bedbrook, Wienczyslawa Czarlewski, Ignacio J. Ansotegui, Karl‐C. Bergmann, Fulvio Braido, Luisa Brussino, Lorenzo Cecchi, Claudia Chaves Loureiro, Alvaro A. Cruz, Philippe Devillier, Alessandro Fiocchi, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Ludger Klimek, Marek Kulus, Piotr Kuna, Maciej Kupczyk, Violeta Kvedariene, Desiree E. Larenas‐Linnemann, Gilles Louis, Renaud Louis, Michael Makris, Mario Morais‐Almeida, Marek Niedoszytko, Ken Ohta, Markus Ollert, Nikolaos Papadopoulos, Vincenzo Patella, Benoit Pétré, Oliver Pfaar, Francesca Puggioni, Santiago Quirce, Frederico S. Regateiro, Nicolas Roche, Philip W. Rouadi, Boleslaw Samolinski, Joaquin Sastre, Florence Schleich, Nicola Scichilone, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Arunas Valiulis, Ilgim Vardaloglu Koyuncu, Maria Teresa Ventura, Arzu Yorgancioglu, Joao A. Fonseca, and Torsten Zuberbier
Subjects: asthma, digital health, EQ‐5D, rhinitis, visual analogue scale, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Patient‐reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person‐centred care. This paper reviews studies performed on PROMs for assessing AR and asthma control, in particular VAS scales that are included in the app MASK‐air® (Mobile Airways Sentinel networK) for asthma and rhinitis. VASs were initially developed on paper and pencil and tested for their criterion validity, cut‐offs and responsiveness. Then, a multicentric, multinational, double‐blind, placebo‐controlled, randomised control trial (DB‐PC‐RCT) using an electronic VAS form was carried out. Finally, with the development of MASK‐air® in 2015, previously validated VAS questions were adapted to the digital format and further methodologic evaluations were performed. VAS for asthma, rhinitis, conjunctivitis, work and EQ‐5D are included in the app. Additionally, two control‐medication scores for allergic symptoms of asthma (e‐DASTHMA) were validated for their criterion validity, cut‐offs and responsiveness.
Published: 2024
Full Text: View/download PDF

3. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK‐air study

Author: Bernardo Sousa‐Pinto, Gilles Louis, Rafael J. Vieira, Wienczyslawa Czarlewski, Josep M. Anto, Rita Amaral, Ana Sá‐Sousa, Luisa Brussino, G. Walter Canonica, Claudia Chaves Loureiro, Alvaro A. Cruz, Bilun Gemicioglu, Tari Haahtela, Maciej Kupczyk, Violeta Kvedariene, Desirée E. Larenas‐Linnemann, Nhân Pham‐Thi, Francesca Puggioni, Frederico S. Regateiro, Jan Romantowski, Joaquin Sastre, Nicola Scichilone, Luis Taborda‐Barata, Maria Teresa Ventura, Ioana Agache, Anna Bedbrook, Alida Benfante, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Matteo Bonini, Louis‐Philippe Boulet, Guy Brusselle, Roland Buhl, Lorenzo Cecchi, Denis Charpin, Elisio M. Costa, Stefano Del Giacco, Marek Jutel, Ludger Klimek, Piotr Kuna, Daniel Laune, Mika Makela, Mario Morais‐Almeida, Rachel Nadif, Marek Niedoszytko, Nikolaos G. Papadopoulos, Alberto Papi, Oliver Pfaar, Daniela Rivero‐Yeverino, Nicolas Roche, Boleslaw Samolinski, Mohamed H. Shamji, Aziz Sheikh, Charlotte Suppli Ulrik, Omar S. Usmani, Arunas Valiulis, Arzu Yorgancioglu, Torsten Zuberbier, Joao A. Fonseca, Benoit Pétré, Renaud Louis, Jean Bousquet, and MASK‐air think tank
Subjects: asthma, diagnosis, dyspnea, mHealth, wheezing, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Rationale It is unclear how each individual asthma symptom is associated with asthma diagnosis or control. Objectives To assess the performance of individual asthma symptoms in the identification of patients with asthma and their association with asthma control. Methods In this cross‐sectional study, we assessed real‐world data using the MASK‐air® app. We compared the frequency of occurrence of five asthma symptoms (dyspnea, wheezing, chest tightness, fatigue and night symptoms, as assessed by the Control of Allergic Rhinitis and Asthma Test [CARAT] questionnaire) in patients with probable, possible or no current asthma. We calculated the sensitivity, specificity and predictive values of each symptom, and assessed the association between each symptom and asthma control (measured using the e‐DASTHMA score). Results were validated in a sample of patients with a physician‐established diagnosis of asthma. Measurement and Main Results We included 951 patients (2153 CARAT assessments), with 468 having probable asthma, 166 possible asthma and 317 no evidence of asthma. Wheezing displayed the highest specificity (90.5%) and positive predictive value (90.8%). In patients with probable asthma, dyspnea and chest tightness were more strongly associated with asthma control than other symptoms. Dyspnea was the symptom with the highest sensitivity (76.1%) and the one consistently associated with the control of asthma as assessed by e‐DASTHMA. Consistent results were observed when assessing patients with a physician‐made diagnosis of asthma. Conclusions Wheezing and chest tightness were the asthma symptoms with the highest specificity for asthma diagnosis, while dyspnea displayed the highest sensitivity and strongest association with asthma control.
Published: 2024
Full Text: View/download PDF

4. Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

Author: Bernardo Sousa-Pinto, PhD, Cristina Jácome, PhD, Ana Margarida Pereira, MD, Frederico S Regateiro, MD, Rute Almeida, PhD, Wienczyslawa Czarlewski, MD, Marek Kulus, ProfMD, Mohamed H Shamji, ProfMD, Louis-Philippe Boulet, ProfMD, Matteo Bonini, MD, Luisa Brussino, MD, G Walter Canonica, ProfMD, Alvaro A Cruz, MD, Bilun Gemicioglu, ProfMD, Tari Haahtela, ProfMD, Maciej Kupczyk, MD, Violeta Kvedariene, MD, Desirée Larenas-Linnemann, MD, Renaud Louis, ProfMD, Marek Niedoszytko, ProfMD, Nhân Pham-Thi, MD, Francesca Puggioni, MD, Jan Romantowski, MD, Joaquin Sastre, ProfMD, Nicola Scichilone, ProfMD, Luis Taborda-Barata, ProfMD, Maria Teresa Ventura, MD, Rafael José Vieira, MD, Ioana Agache, ProfMD, Anna Bedbrook, BSc, Karl C Bergmann, MD, Rita Amaral, PhD, Luís Filipe Azevedo, PhD, Sinthia Bosnic-Anticevich, ProfPhD, Guy Brusselle, ProfMD, Roland Buhl, ProfMD, Lorenzo Cecchi, MD, Denis Charpin, MD, Claudia Chaves Loureiro, MD, Frédéric de Blay, ProfMD, Stefano Del Giacco, ProfMD, Philippe Devillier, ProfMD, Ewa Jassem, ProfMD, Guy Joos, ProfMD, Marek Jutel, ProfMD, Ludger Klimek, MD, Piotr Kuna, ProfMD, Daniel Laune, PhD, Jorge Luna Pech, MD, Mika Makela, ProfMD, Mario Morais-Almeida, MD, Rachel Nadif, PhD, Hugo E Neffen, MD, Ken Ohta, ProfMD, Nikolaos G Papadopoulos, ProfMD, Alberto Papi, ProfMD, Benoit Pétré, MD, Oliver Pfaar, MD, Daniela Rivero Yeverino, MD, Carlos Robalo Cordeiro, ProfMD, Nicolas Roche, ProfMD, Ana Sá-Sousa, PhD, Boleslaw Samolinski, ProfMD, Aziz Sheikh, ProfMD, Charlotte Suppli Ulrik, ProfMD, Omar S Usmani, ProfMD, Arunas Valiulis, ProfMD, Olivier Vandenplas, ProfMD, Pedro Vieira-Marques, PhD, Arzu Yorgancioglu, ProfMD, Torsten Zuberbier, ProfMD, Josep M Anto, ProfMD, João A Fonseca, PhD, and Jean Bousquet, ProfMD
Subjects: Computer applications to medicine. Medical informatics, R858-859.7
Abstract: Summary: Background: Validated questionnaires are used to assess asthma control over the past 1–4 weeks from reporting. However, they do not adequately capture asthma control in patients with fluctuating symptoms. Using the Mobile Airways Sentinel Network for airway diseases (MASK-air) app, we developed and validated an electronic daily asthma control score (e-DASTHMA). Methods: We used MASK-air data (freely available to users in 27 countries) to develop and assess different daily control scores for asthma. Data-driven control scores were developed based on asthma symptoms reported by a visual analogue scale (VAS) and self-reported asthma medication use. We included the daily monitoring data from all MASK-air users aged 16–90 years (or older than 13 years to 90 years in countries with a lower age of digital consent) who had used the app in at least 3 different calendar months and had reported at least 1 day of asthma medication use. For each score, we assessed construct validity, test–retest reliability, responsiveness, and accuracy. We used VASs on dyspnoea and work disturbance, EQ-5D-VAS, Control of Allergic Rhinitis and Asthma Test (CARAT), CARAT asthma, and Work Productivity and Activity Impairment: Allergy Specific (WPAI:AS) questionnaires as comparators. We performed an internal validation using MASK-air data from Jan 1 to Oct 12, 2022, and an external validation using a cohort of patients with physician-diagnosed asthma (the INSPIRERS cohort) who had had their diagnosis and control (Global Initiative for Asthma [GINA] classification) of asthma ascertained by a physician. Findings: We studied 135 635 days of MASK-air data from 1662 users from May 21, 2015, to Dec 31, 2021. The scores were strongly correlated with VAS dyspnoea (Spearman correlation coefficient range 0·68–0·82) and moderately correlated with work comparators and quality-of-life-related comparators (for WPAI:AS work, we observed Spearman correlation coefficients of 0·59–0·68). They also displayed high test–retest reliability (intraclass correlation coefficients range 0·79–0·95) and moderate-to-high responsiveness (correlation coefficient range 0·69–0·79; effect size measures range 0·57–0·99 in the comparison with VAS dyspnoea). The best-performing score displayed a strong correlation with the effect of asthma on work and school activities in the INSPIRERS cohort (Spearman correlation coefficients 0·70; 95% CI 0·61–0·78) and good accuracy for the identification of patients with uncontrolled or partly controlled asthma according to GINA (area under the receiver operating curve 0·73; 95% CI 0·68–0·78). Interpretation: e-DASTHMA is a good tool for the daily assessment of asthma control. This tool can be used as an endpoint in clinical trials as well as in clinical practice to assess fluctuations in asthma control and guide treatment optimisation. Funding: None.
Published: 2023
Full Text: View/download PDF

5. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air® approach

Author: Jean Bousquet, Josep M. Anto, Bernardo Sousa‐Pinto, Wienczyslawa Czarlewski, Anna Bedbrook, Tari Haahtela, Ludger Klimek, Oliver Pfaar, Piotr Kuna, Maciej Kupczyk, Frederico S. Regateiro, Boleslaw Samolinski, Arunas Valiulis, Arzu Yorgancioglu, Sylvie Arnavielhe, Xavier Basagaña, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Luisa Brussino, G. Walter Canonica, Victoria Cardona, Lorenzo Cecchi, Claudia Chaves‐Loureiro, Elisio Costa, Alvaro A. Cruz, Bilun Gemicioglu, Wytske J. Fokkens, Juan Carlos Ivancevich, Helga Kraxner, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Daniel Laune, Renaud Louis, Michael Makris, Marcus Maurer, Erik Melén, Yann Micheli, Mario Morais‐Almeida, Joaquim Mullol, Marek Niedoszytko, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Philip W. Rouadi, Joaquin Sastre, Nicola Scichilone, Aziz Sheikh, Mikhail Sofiev, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Ioanna Tsiligianni, Erkka Valovirta, Maria Teresa Ventura, Rafael José Vieira, Mihaela Zidarn, Rita Amaral, Ignacio J. Ansotegui, Annabelle Bédard, Samuel Benveniste, Michael Bewick, Carsten Bindslev‐Jensen, Hubert Blain, Matteo Bonini, Rodolphe Bourret, Fulvio Braido, Pedro Carreiro‐Martins, Denis Charpin, Ivan Cherrez‐Ojeda, Tomas Chivato, Derek K. Chu, Cemal Cingi, Stefano DelGiacco, Frédéric deBlay, Philippe Devillier, Govert DeVries, Maria Doulaptsi, Virginie Doyen, Gérard Dray, Jean‐François Fontaine, R. Maximiliano Gomez, Jan Hagemann, Enrico Heffler, Maja Hofmann, Ewa Jassem, Marek Jutel, Thomas Keil, Vicky Kritikos, Inger Kull, Marek Kulus, Olga Lourenço, Eve Mathieu‐Dupas, Enrica Menditto, Ralph Mösges, Ruth Murray, Rachel Nadif, Hugo Neffen, Stefania Nicola, Robyn O’Hehir, Heidi Olze, Yuliia Palamarchuk, Jean‐Louis Pépin, Benoit Pétré, Robert Picard, Constantinos Pitsios, Francesca Puggioni, Santiago Quirce, Filip Raciborski, Sietze Reitsma, Nicolas Roche, Monica Rodriguez‐Gonzalez, Jan Romantowski, Ana Sá‐Sousa, Faradiba S. Serpa, Marine Savouré, Mohamed H. Shamji, Milan Sova, Annette Sperl, Cristiana Stellato, Ana Todo‐Bom, Peter Valentin Tomazic, Olivier Vandenplas, Michiel VanEerd, Tuula Vasankari, Frédéric Viart, Susan Waserman, Joao A. Fonseca, and Torsten Zuberbier
Subjects: asthma, digital, MASK‐air, mHealth, rhinitis, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract MASK‐air®, a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK‐air® is a Good Practice of DG Santé on digitally‐enabled, patient‐centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co‐operation and Development). MASK‐air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK‐air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as‐needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom‐medication score (ARIA‐EAACI‐CSMS) has been validated for clinical practice and trials. The implications of the novel MASK‐air® results should lead to change management in rhinitis and asthma.
Published: 2023
Full Text: View/download PDF

6. Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

Author: Bernardo Sousa‐Pinto, Aram Anto, Markus Berger, Stephanie Dramburg, Oliver Pfaar, Ludger Klimek, Marek Jutel, Wienczyslawa Czarlewski, Anna Bedbrook, Arunas Valiulis, Ioana Agache, Rita Amaral, Ignacio J. Ansotegui, Katharina Bastl, Uwe Berger, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Fulvio Braido, Luisa Brussino, Victoria Cardona, Thomas Casale, G. Walter Canonica, Lorenzo Cecchi, Denis Charpin, Tomás Chivato, Derek K. Chu, Cemal Cingi, Elisio M. Costa, Alvaro A. Cruz, Philippe Devillier, Stephen R. Durham, Motohiro Ebisawa, Alessandro Fiocchi, Wytske J. Fokkens, Bilun Gemicioğlu, Maia Gotua, Maria‐Antonieta Guzmán, Tari Haahtela, Juan Carlos Ivancevich, Piotr Kuna, Igor Kaidashev, Musa Khaitov, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Brian Lipworth, Daniel Laune, Paolo M. Matricardi, Mario Morais‐Almeida, Joaquim Mullol, Robert Naclerio, Hugo Neffen, Kristoff Nekam, Marek Niedoszytko, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Hae‐Sim Park, Giovanni Passalacqua, Vincenzo Patella, Simone Pelosi, Nhân Pham‐Thi, Ted A. Popov, Frederico S. Regateiro, Sietze Reitsma, Monica Rodriguez‐Gonzales, Nelson Rosario, Philip W. Rouadi, Boleslaw Samolinski, Ana Sá‐Sousa, Joaquin Sastre, Aziz Sheikh, Charlotte Suppli Ulrik, Luis Taborda‐Barata, Ana Todo‐Bom, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Salvatore Tripodi, Ioanna Tsiligianni, Erkka Valovirta, Maria Teresa Ventura, Antonio A. Valero, Rafael José Vieira, Dana Wallace, Susan Waserman, Sian Williams, Arzu Yorgancioglu, Luo Zhang, Mihaela Zidarn, Jaron Zuberbier, Heidi Olze, Josep M. Antó, Torsten Zuberbier, João A. Fonseca, and Jean Bousquet
Subjects: allergic rhinitis, app, chronic rhinosinusitis, mHealth, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Digital health is an umbrella term which encompasses eHealth and benefits from areas such as advanced computer sciences. eHealth includes mHealth apps, which offer the potential to redesign aspects of healthcare delivery. The capacity of apps to collect large amounts of longitudinal, real‐time, real‐world data enables the progression of biomedical knowledge. Apps for rhinitis and rhinosinusitis were searched for in the Google Play and Apple App stores, via an automatic market research tool recently developed using JavaScript. Over 1500 apps for allergic rhinitis and rhinosinusitis were identified, some dealing with multimorbidity. However, only six apps for rhinitis (AirRater, AllergyMonitor, AllerSearch, Husteblume, MASK‐air and Pollen App) and one for rhinosinusitis (Galenus Health) have so far published results in the scientific literature. These apps were reviewed for their validation, discovery of novel allergy phenotypes, optimisation of identifying the pollen season, novel approaches in diagnosis and management (pharmacotherapy and allergen immunotherapy) as well as adherence to treatment. Published evidence demonstrates the potential of mobile health apps to advance in the characterisation, diagnosis and management of rhinitis and rhinosinusitis patients.
Published: 2022
Full Text: View/download PDF

7. Type 2 inflammation in asthma and other airway diseases

Author: Jorge Maspero, Yochai Adir, Mona Al-Ahmad, Carlos A. Celis-Preciado, Federico D. Colodenco, Pedro Giavina-Bianchi, Hani Lababidi, Olivier Ledanois, Bassam Mahoub, Diahn-Warng Perng, Juan C. Vazquez, and Arzu Yorgancioglu
Subjects: Medicine
Abstract: Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic COPD and allergic rhinitis are a global health concern. Despite the coexistence of these diseases and their common pathophysiology, they are often managed independently, resulting in poor asthma control, continued symptoms and poor quality of life. Understanding disease pathophysiology is important for best treatment practice, reduced disease burden and improved patient outcomes. The pathophysiology of type 2 inflammation is driven by both the innate immune system triggered by pollutants, viral or fungal infections involving type 2 innate lymphoid cells (ILC2) and the adaptive immune system, triggered by contact with an allergen involving type 2 T-helper (Th2) cells. Both ILC2 and Th2 cells produce the type-2 cytokines (interleukin (IL)-4, IL-5 and IL-13), each with several roles in the inflammation cascade. IL-4 and IL-13 cause B-cell class switching and IgE production, release of pro-inflammatory mediators, barrier disruption and tissue remodelling. In addition, IL-13 causes goblet-cell hyperplasia and mucus production. All three interleukins are involved in trafficking eosinophils to tissues, producing clinical symptoms characteristic of chronic inflammatory airway diseases. Asthma is a heterogenous disease; therefore, identification of biomarkers and early targeted treatment is critical for patients inadequately managed by inhaled corticosteroids and long-acting β-agonists alone. The Global Initiative for Asthma guidelines recommend add-on biological (anti IgE, IL-5/5R, IL-4R) treatments for those not responding to standard of care. Targeted therapies, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab, were developed on current understanding of the pathophysiology of type 2 inflammation. These therapies offer hope for improved management of type 2 inflammatory airway diseases.
Published: 2022
Full Text: View/download PDF

8. Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD

Author: Alfredo Chetta, Arzu Yorgancioglu, Mario Scuri, Sara Barile, Daniele Guastalla, and P. N. Richard Dekhuijzen
Subjects: Dry powder inhalers, Asthma, Chronic obstructive pulmonary disease, Inspiratory flow, Breath-actuated mechanism, Diseases of the respiratory system, RC705-779
Abstract: Abstract Background Inhaler selection is important when managing respiratory conditions; a patient’s inhalation technique should be appropriate for the selected device, and patients should ideally be able to use a device successfully regardless of disease severity. The NEXThaler is a multidose dry-powder inhaler with a breath-actuated mechanism (BAM) and dose counter that activates only following inhalation, so effectively an ‘inhalation counter’. We assessed inspiratory flow through the NEXThaler in two studies and examined whether inhalation triggered the BAM. Methods The two studies were open-label, single-arm, and single visit. One study recruited patients with asthma aged ≥ 18 years; the other recruited patients with chronic obstructive pulmonary disease (COPD) aged ≥ 40 years. All patients inhaled twice through a placebo NEXThaler. The inspiratory profile through the device was assessed for each inhalation using acoustic monitoring, with flow at and time to BAM firing, peak inspiratory flow (PIF), and total inhalation time assessed. Results A total of 40 patients were enrolled in the asthma study: 20 with controlled asthma and 20 with partly controlled/uncontrolled asthma. All patients were able to trigger the BAM, as evidenced by the inhalation counter activating on closing the device. Mean flow at BAM firing following first inhalation was 35.0 (range 16.3–52.3) L/min; mean PIF was 64.6 (35.0–123.9) L/min. A total of 72 patients were enrolled in the COPD study, with data analysed for 69 (mean forced expiratory volume in 1 s 48.7% predicted [17–92%]). As with the asthma study, all patients, regardless of airflow limitation, were able to trigger the BAM. Mean flow at BAM firing following first inhalation was 41.9 (26.6–57.1) L/min; mean PIF was 68.0 (31.5–125.4) L/min. Device usability was rated highly in both studies, with 5 min sufficient to train the patients, and a click heard shortly after inhalation in all cases (providing feedback on BAM firing). Conclusions Inhalation flows triggering the BAM in the NEXThaler were similar between patients with controlled and partly controlled/uncontrolled asthma, and were similar across COPD airflow limitation. All enrolled patients were able to activate the device.
Published: 2021
Full Text: View/download PDF

9. Allergen immunotherapy in MASK‐air users in real‐life: Results of a Bayesian mixed‐effects model

Author: Bernardo Sousa‐Pinto, Luís Filipe Azevedo, Ana Sá‐Sousa, Rafael José Vieira, Rita Amaral, Ludger Klimek, Wienczyslawa Czarlewski, Josep M. Anto, Anna Bedbrook, Violeta Kvedariene, Maria Teresa Ventura, Ignacio J. Ansotegui, Karl‐Christian Bergmann, Luisa Brussino, G. Walter Canonica, Victoria Cardona, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Tomás Chivato, Derek K. Chu, Cemal Cingi, Elisio M. Costa, Alvaro A. Cruz, Giulia De Feo, Philippe Devillier, Wytske J. Fokkens, Mina Gaga, Bilun Gemicioğlu, Tari Haahtela, Juan Carlos Ivancevich, Zhanat Ispayeva, Marek Jutel, Piotr Kuna, Igor Kaidashev, Helga Kraxner, Désirée E. Larenas‐Linnemann, Daniel Laune, Brian Lipworth, Renaud Louis, Michaël Makris, Riccardo Monti, Mario Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Mikaëla Odemyr, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Milan Sova, Ana Todo‐Bom, Luis Taborda‐Barata, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, João Almeida Fonseca, Jean Bousquet, and Oliver Pfaar
Subjects: allergic rhinitis, immunotherapy, mobile health, patient‐reported outcomes, real‐life data analysis, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Background Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real‐life studies. Objective To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK‐air® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT. Methods We assessed the MASK‐air® data of European users with self‐reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales—VASs), and a combined symptom‐medication score (CSMS). We applied Bayesian mixed‐effects models, with clustering by patient, country and pollen season. Results We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT‐tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = −12.1;−2.8), lower VAS Work (average difference = 5.0; 95%CrI = −8.5;−1.5), and a lower CSMS (average difference = 3.7; 95%CrI = −9.3;2.2). When compared to SCIT, SLIT‐tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = −17.2;−2.8), lower VAS Work (average difference = 7.8; 95%CrI = −15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = −18.5;0.2). Conclusion In patients with grass pollen allergy, SLIT‐tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally‐harmonised standards for performing and reporting real‐world data in AIT are needed to better understand its ‘real‐world’ effectiveness.
Published: 2022
Full Text: View/download PDF

10. Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Author: Jean Bousquet, Josep M. Anto, Guido Iaccarino, Wienczyslawa Czarlewski, Tari Haahtela, Aram Anto, Cezmi A. Akdis, Hubert Blain, G. Walter Canonica, Victoria Cardona, Alvaro A. Cruz, Maddalena Illario, Juan Carlos Ivancevich, Marek Jutel, Ludger Klimek, Piotr Kuna, Daniel Laune, Désirée Larenas-Linnemann, Joaquim Mullol, Nikos G. Papadopoulos, Oliver Pfaar, Boleslaw Samolinski, Arunas Valiulis, Arzu Yorgancioglu, Torsten Zuberbier, and The ARIA group
Subjects: Coronavirus, Diet, Angiotensin-converting enzyme, Antioxidant, Food, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Reported COVID-19 deaths in Germany are relatively low as compared to many European countries. Among the several explanations proposed, an early and large testing of the population was put forward. Most current debates on COVID-19 focus on the differences among countries, but little attention has been given to regional differences and diet. The low-death rate European countries (e.g. Austria, Baltic States, Czech Republic, Finland, Norway, Poland, Slovakia) have used different quarantine and/or confinement times and methods and none have performed as many early tests as Germany. Among other factors that may be significant are the dietary habits. It seems that some foods largely used in these countries may reduce angiotensin-converting enzyme activity or are anti-oxidants. Among the many possible areas of research, it might be important to understand diet and angiotensin-converting enzyme-2 (ACE2) levels in populations with different COVID-19 death rates since dietary interventions may be of great benefit.
Published: 2020
Full Text: View/download PDF

11. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK‐air®

Author: Bernardo Sousa‐Pinto, Patrik Eklund, Oliver Pfaar, Ludger Klimek, Torsten Zuberbier, Wienczyslawa Czarlewski, Annabelle Bédard, Carsten Bindslev‐Jensen, Anna Bedbrook, Sinthia Bosnic‐Anticevich, Luisa Brussino, Victoria Cardona, Alvaro A. Cruz, Govert deVries, Philippe Devillier, Wytske J. Fokkens, José Miguel Fuentes‐Pérez, Bilun Gemicioğlu, Tari Haahtela, Yunen Rocío Huerta‐Villalobos, Juan Carlos Ivancevich, Inger Kull, Piotr Kuna, Violeta Kvedariene, Désirée E. Larenas Linnemann, Daniel Laune, Michael Makris, Erik Melén, Mário Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Robyn E. O'Hehir, Nikolaos G. Papadopoulos, Ana Margarida Pereira, Emmanuel P. Prokopakis, Fotis Psarros, Frederico S. Regateiro, Sietze Reitsma, Boleslaw Samolinski, Nicola Scichilone, Jane daSilva, Cristiana Stellato, Ana Todo‐Bom, Peter Valentin Tomazic, Sanna Toppila Salmi, Antonio Valero, Arunas Valiulis, Erkka Valovirta, Michiel vanEerd, Maria Teresa Ventura, Arzu Yorgancioglu, Xavier Basagaña, Josep M. Antó, Jean Bousquet, and João Almeida Fonseca
Subjects: allergic rhinitis, mobile health, reliability, responsiveness, visual analog scales, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Background MASK‐air® is an app that supports allergic rhinitis patients in disease control. Users register daily allergy symptoms and their impact on activities using visual analog scales (VASs). We aimed to assess the concurrent validity, reliability, and responsiveness of these daily VASs. Methods Daily monitoring VAS data were assessed in MASK‐air® users with allergic rhinitis. Concurrent validity was assessed by correlating daily VAS values with those of the EuroQol‐5 Dimensions (EQ‐5D) VAS, the Control of Allergic Rhinitis and Asthma Test (CARAT) score, and the Work Productivity and Activity Impairment Allergic Specific (WPAI‐AS) Questionnaire (work and activity impairment scores). Intra‐rater reliability was assessed in users providing multiple daily VASs within the same day. Test–retest reliability was tested in clinically stable users, as defined by the EQ‐5D VAS, CARAT, or “VAS Work” (i.e., VAS assessing the impact of allergy on work). Responsiveness was determined in users with two consecutive measurements of EQ‐5D‐VAS or “VAS Work” indicating clinical change. Results A total of 17,780 MASK‐air® users, with 317,176 VAS days, were assessed. Concurrent validity was moderate–high (Spearman correlation coefficient range: 0.437–0.716). Intra‐rater reliability intraclass correlation coefficients (ICCs) ranged between 0.870 (VAS assessing global allergy symptoms) and 0.937 (VAS assessing allergy symptoms on sleep). Test–retest reliability ICCs ranged between 0.604 and 0.878—“VAS Work” and “VAS asthma” presented the highest ICCs. Moderate/large responsiveness effect sizes were observed—the sleep VAS was associated with lower responsiveness, while the global allergy symptoms VAS demonstrated higher responsiveness. Conclusion In MASK‐air®, daily monitoring VASs have high intra‐rater reliability and moderate–high validity, reliability, and responsiveness, pointing to a reliable measure of symptom loads.
Published: 2021
Full Text: View/download PDF

12. ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

Author: Jean Bousquet, Oliver Pfaar, Ioana Agache, Anna Bedbrook, Cezmi A Akdis, G. Walter Canonica, Tomas Chivato, Mona Al‐Ahmad, Amir H Abdul Latiff, Ignacio J Ansotegui, Claus Bachert, Abdullah Baharuddin, Karl‐Christian Bergmann, Carsten Bindslev‐Jensen, Leif Bjermer, Matteo Bonini, Sinthia Bosnic‐Anticevich, Isabelle Bosse, Helen A. Brough, Luisa Brussino, Moises A Calderon, Luis Caraballo, Victoria Cardona, Pedro Carreiro‐Martins, Tomas Casale, Lorenzo Cecchi, Alfonso M Cepeda Sarabia, Ekaterine Chkhartishvili, Derek K Chu, Ieva Cirule, Alvaro A Cruz, Wienczyslawa Czarlewski, Stefano delGiacco, Pascal Demoly, Philippe Devillier, Dejan Dokic, Stephen L Durham, Motohiro Ebisawa, Yehia El‐Gamal✝, Regina Emuzyte, Amiran Gamkrelidze, Jean Luc Fauquert, Alessandro Fiocchi, Wytske J Fokkens, Joao A Fonseca, Jean‐François Fontaine, Radoslaw Gawlik, Asli Gelincik, Bilun Gemicioglu, Jose E Gereda, Roy Gerth van Wijk, R Maximiliano Gomez, Maia Gotua, Ineta Grisle, Maria‐Antonieta Guzmán, Tari Haahtela, Susanne Halken, Enrico Heffler, Karin Hoffmann‐Sommergruber, Elham Hossny, Martin Hrubiško, Carla Irani, Juan Carlos Ivancevich, Zhanat Ispayeva, Kaja Julge, Igor Kaidashev, Omer Kalayci, Musa Khaitov, Ludger Klimek, Edward Knol, Marek L Kowalski, Helga Kraxner, Inger Kull, Piotr Kuna, Violeta Kvedariene, Vicky Kritikos, Antti Lauerma, Susanne Lau, Daniel Laune, Michael Levin, Desiree E Larenas‐Linnemann, Karin C Lodrup Carlsen, Carlo Lombardi, Olga M Lourenço, Bassam Mahboub, Hans‐Jørgen Malling, Patrick Manning, Gailen D Marshall, Erik Melén, Eli O Meltzer, Neven Miculinic, Branislava Milenkovic, Mostafa Moin, Stephen Montefort, Mario Morais‐Almeida, Charlotte G Mortz, Ralph Mösges, Joaquim Mullol, Leyla Namazova Baranova, Hugo Neffen, Kristof Nekam, Marek Niedoszytko, Mikaëla Odemyr, Robyn E O'Hehir, Markus Ollert, Liam O'Mahony, Ken Ohta, Yoshitaka Okamoto, Kimi Okubo, Giovanni B Pajno, Oscar Palomares, Susanna Palkonen, Petr Panzner, Nikolaos GPapadopoulos, Hae‐Sim Park, Giovanni Passalacqua, Vincenzo Patella, Ruby Pawankar, Nhân Pham‐Thi, Davor Plavec, Todor A Popov, Marysia Recto, Frederico S Regateiro, Carmen Riggioni, Graham Roberts, Monica Rodriguez‐Gonzales, Nelson Rosario, Menachem Rottem, Philip W Rouadi, Dermot Ryan, Boleslaw Samolinski, Mario Sanchez‐Borges✝, Faradiba S Serpa, Joaquin Sastre, Glenis K. Scadding, Mohamed H Shamji, Peter Schmid‐Grendelmeier, Holger J Schünemann, Aziz Sheikh, Nicola Scichilone, Juan Carlos Sisul, Mikhail Sofiev, Dirceu Solé, Talant Sooronbaev, Manuel Soto‐Martinez, Manuel Soto‐Quiros, Milan Sova, Jürgen Schwarze, Isabel Skypala, Charlotte Suppli‐Ulrik, Luis Taborda‐Barata, Ana Todo‐Bom, Maria J Torres, Marylin Valentin‐Rostan, Peter‐Valentin Tomazic, Antonio Valero, Sanna Toppila‐Salmi, Ioanna Tsiligianni, Eva Untersmayr, Marilyn Urrutia‐Pereira, Arunas Valiulis, Erkka Valovirta, Olivier Vandenplas, Maria Teresa Ventura, Pakit Vichyanond, Martin Wagenmann, Dana Wallace, Jolanta Walusiak‐Skorupa, De Yun Wang, Susan Waserman, Gary WK Wong, Arzu Yorgancioglu, Osman M Yusuf, Mario Zernotti, Luo Zhang, Mihaela Zidarn, Torsten Zuberbier, and Marek Jutel
Subjects: allergic rhinitis, asthma, immunotherapy, precision medicine, Immunologic diseases. Allergy, RC581-607
Published: 2021
Full Text: View/download PDF

13. Correction to: Is diet partly responsible for differences in COVID-19 death rates between and within countries?

Author: Jean Bousquet, Josep M. Anto, Guido Iaccarino, Wienczyslawa Czarlewski, Tari Haahtela, Aram Anto, Cezmi A. Akdis, Hubert Blain, G. Walter Canonica, Victoria Cardona, Alvaro A. Cruz, Maddalena Illario, Juan Carlos Ivancevich, Marek Jutel, Ludger Klimek, Piotr Kuna, Daniel Laune, Désirée Larenas‑Linnemann, Joaquim Mullol, Nikos G. Papadopoulos, Oliver Pfaar, Boleslaw Samolinski, Arunas Valiulis, Arzu Yorgancioglu, Torsten Zuberbier, and The ARIA group
Subjects: Immunologic diseases. Allergy, RC581-607
Abstract: An amendment to this paper has been published and can be accessed via the original article.
Published: 2020
Full Text: View/download PDF

14. The Global Alliance against Chronic Respiratory Diseases: journey so far and way ahead

Author: Arzu Yorgancioglu, Nikolai Khaltaev, Jean Bousquet, Cherian Varghese, and Qiang Shi
Subjects: Medicine
Published: 2020
Full Text: View/download PDF

15. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases

Author: J. Jean Bousquet, Holger J. Schünemann, Alkis Togias, Marina Erhola, Peter W. Hellings, Torsten Zuberbier, Ioana Agache, Ignacio J. Ansotegui, Josep M. Anto, Claus Bachert, Sven Becker, Martin Bedolla-Barajas, Michael Bewick, Sinthia Bosnic-Anticevich, Isabelle Bosse, Louis P. Boulet, Jean Marc Bourrez, Guy Brusselle, Niels Chavannes, Elisio Costa, Alvaro A. Cruz, Wienczyslawa Czarlewski, Wytske J. Fokkens, Joao A. Fonseca, Mina Gaga, Tari Haahtela, Maddalena Illario, Ludger Klimek, Piotr Kuna, Violeta Kvedariene, L. T. T. Le, Desiree Larenas-Linnemann, Daniel Laune, Olga M. Lourenço, Enrica Menditto, Joaquin Mullol, Yashitaka Okamoto, Nikos Papadopoulos, Nhân Pham-Thi, Robert Picard, Hilary Pinnock, Nicolas Roche, Regina E. Roller-Wirnsberger, Christine Rolland, Boleslaw Samolinski, Aziz Sheikh, Sanna Toppila-Salmi, Ioanna Tsiligianni, Arunas Valiulis, Erkka Valovirta, Tuula Vasankari, Maria-Teresa Ventura, Samantha Walker, Sian Williams, Cezmi A. Akdis, Isabella Annesi-Maesano, Sylvie Arnavielhe, Xavier Basagana, Eric Bateman, Anna Bedbrook, K. S. Bennoor, Samuel Benveniste, Karl C. Bergmann, Slawomir Bialek, Nils Billo, Carsten Bindslev-Jensen, Leif Bjermer, Hubert Blain, Mateo Bonini, Philippe Bonniaud, Jacques Bouchard, Vitalis Briedis, Christofer E. Brightling, Jan Brozek, Roland Buhl, Roland Buonaiuto, Giorgo W. Canonica, Victoria Cardona, Ana M. Carriazo, Warner Carr, Christine Cartier, Thomas Casale, Lorenzo Cecchi, Alfonso M. Cepeda Sarabia, Eka Chkhartishvili, Derek K. Chu, Cemal Cingi, Elaine Colgan, Jaime Correia de Sousa, Anne Lise Courbis, Adnan Custovic, Biljana Cvetkosvki, Gennaro D’Amato, Jane da Silva, Carina Dantas, Dejand Dokic, Yves Dauvilliers, Antoni Dedeu, Giulia De Feo, Philippe Devillier, Stefania Di Capua, Marc Dykewickz, Ruta Dubakiene, Motohiro Ebisawa, Yaya El-Gamal, Esben Eller, Regina Emuzyte, John Farrell, Antjie Fink-Wagner, Alessandro Fiocchi, Jean F. Fontaine, Bilun Gemicioğlu, Peter Schmid-Grendelmeir, Amiran Gamkrelidze, Judith Garcia-Aymerich, Maximiliano Gomez, Sandra González Diaz, Maia Gotua, Nick A. Guldemond, Maria-Antonieta Guzmán, Jawad Hajjam, John O’B Hourihane, Marc Humbert, Guido Iaccarino, Despo Ierodiakonou, Juan C. Ivancevich, Guy Joos, Ki-Suck Jung, Marek Jutel, Igor Kaidashev, Omer Kalayci, Przemyslaw Kardas, Thomas Keil, Mussa Khaitov, Nikolai Khaltaev, Jorg Kleine-Tebbe, Marek L. Kowalski, Vicky Kritikos, Inger Kull, Lisa Leonardini, Philip Lieberman, Brian Lipworth, Karin C. Lodrup Carlsen, Claudia C. Loureiro, Renaud Louis, Alpana Mair, Gert Marien, Bassam Mahboub, Joao Malva, Patrick Manning, Esteban De Manuel Keenoy, Gailen D. Marshall, Mohamed R. Masjedi, Jorge F. Maspero, Eve Mathieu-Dupas, Poalo M. Matricardi, Eric Melén, Elisabete Melo-Gomes, Eli O. Meltzer, Jacques Mercier, Neven Miculinic, Florin Mihaltan, Branislava Milenkovic, Giuliana Moda, Maria-Dolores Mogica-Martinez, Yousser Mohammad, Steve Montefort, Ricardo Monti, Mario Morais-Almeida, Ralf Mösges, Lars Münter, Antonella Muraro, Ruth Murray, Robert Naclerio, Luigi Napoli, Leila Namazova-Baranova, Hugo Neffen, Kristoff Nekam, Angelo Neou, Enrico Novellino, Dieudonné Nyembue, Robin O’Hehir, Ken Ohta, Kimi Okubo, Gabrielle Onorato, Solange Ouedraogo, Isabella Pali-Schöll, Susanna Palkonen, Peter Panzner, Hae-Sim Park, Jean-Louis Pépin, Ana-Maria Pereira, Oliver Pfaar, Ema Paulino, Jim Phillips, Davor Plavec, Ted A. Popov, Fabienne Portejoie, David Price, Emmanuel P. Prokopakis, Benoit Pugin, Filip Raciborski, Rojin Rajabian-Söderlund, Sietze Reitsma, Xavier Rodo, Antonino Romano, Nelson Rosario, Menahenm Rottem, Dermot Ryan, Johanna Salimäki, Mario M. Sanchez-Borges, Juan-Carlos Sisul, Dirceu Solé, David Somekh, Talant Sooronbaev, Milan Sova, Otto Spranger, Cristina Stellato, Rafael Stelmach, Charlotte Suppli Ulrik, Michel Thibaudon, Teresa To, Ana Todo-Bom, Peter V. Tomazic, Antonio A. Valero, Rudolph Valenta, Marylin Valentin-Rostan, Rianne van der Kleij, Olivier Vandenplas, Giorgio Vezzani, Frédéric Viart, Giovanni Viegi, Dana Wallace, Martin Wagenmann, De Y. Wang, Susan Waserman, Magnus Wickman, Dennis M. Williams, Gary Wong, Piotr Wroczynski, Panayiotis K. Yiallouros, Arzu Yorgancioglu, Osman M. Yusuf, Heahter J. Zar, Stéphane Zeng, Mario Zernotti, Luo Zhang, Nan S. Zhong, Mihaela Zidarn, the ARIA Study Group, and the MASK Study Group
Subjects: Health care transformation, Care pathways, Rhinitis, ARIA, MASK, POLLAR, Immunologic diseases. Allergy, RC581-607
Abstract: Abstract Background In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system into integrated care with organizational health literacy. Main body As an example for chronic disease care, MASK (Mobile Airways Sentinel NetworK), a new project of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life ICPs centred around the patient with rhinitis, and using mHealth to monitor environmental exposure. Three aspects of care pathways are being developed: (i) Patient participation, health literacy and self-care through technology-assisted “patient activation”, (ii) Implementation of care pathways by pharmacists and (iii) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) obtained through mobile technology. The EU and global political agendas are of great importance in supporting the digital transformation of health and care, and MASK has been recognized by DG Santé as a Good Practice in the field of digitally-enabled, integrated, person-centred care. Conclusion In 20 years, ARIA has considerably evolved from the first multimorbidity guideline in respiratory diseases to the digital transformation of health and care with a strong political involvement.
Published: 2019
Full Text: View/download PDF

16. Research priorities in α1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration

Author: Miriam Barrecheguren, Karen O'Hara, Marion Wilkens, Jeanette Boyd, Ewa Kolda, Beatriz Lara, Joanna Chorostowska-Wynimko, Ilaria Ferrarotti, Jan Chlumský, Christian Clarenbach, Timm Greulich, Marc Miravitlles, Maria Sucena, Members of EARCO CRC Timm Greulich (Germany, co-chair) Marc Miravitlles (Spain co-chair). Steering committee:, Joanna Chorostowska-Wymiko (Poland), Ilaria Ferrarotti (Italy), Noel G. McElvaney (Ireland), Karen O'Hara (UKpatients' representative), Jan Stolk (Netherlands), Robert A. Stockley, Alice Turner (UK), Marion Wilkens (Germany patients' representative), EARCO members:, Angelo Corsico, Luciano Corda (Italy), Maria Sucena (Portugal), Miriam Barrecheguren (Spain ERS early career representative), Cristina Esquinas (Spain), David Parr, Ravi Mahadeva (UK), Jan Chlumsky (Czech Republic), Sabina Janciauskiene, Robert Bals (Germany), Jens Ulrik Jensen (Denmark), Kostas Kostikas (Greece), Malcolm Kohler, Christian Clarenbach (Switzerland), Alan Altraja (Estonia), Wim Jenssens, Silvia Pérez-Bogerd (Belgium), Caroline Gouder (Malta), Ana Hecimovic (Croatia), Aleksandra Dudvarski (Serbia), Alvils Krams (Latvia), Ruxandra Ulmeanu, Ana Zaharie (Rumania), Jean-François Mornex (France), Arzu Yorgancioglu (Tukey), Karin Schmid-Scherzer (Austria), Hanan Tanash, Eeva Piitulainen (Sweden), Oleksandr Mazulov (Ukraine), and Yavor Ivanov (Bulgaria)
Subjects: Medicine
Abstract: α1-antitrypsin deficiency (AATD) is a rare and under-recognised genetic condition. Owing to its low prevalence, international initiatives are key for conducting high-quality research in the field. From July 2018 to December 2019, the European Alpha-1 Research Collaboration (EARCO) developed and conducted two surveys, one for healthcare providers and one for patients and caregivers, aiming to identify research priorities and barriers in access to treatment for AATD. A survey on 164 research questions was electronically sent to 230 AATD experts in Europe, and 94 completed surveys from 24 countries were received. The top research areas identified by healthcare providers were causes of variable progression and poor outcomes, improvement in diagnosis, initiation and optimal dosing of augmentation therapy and effectiveness of self-management interventions. During the same period, 438 surveys were completed by patients and caregivers from 26 countries. The top research areas identified were improving knowledge about AATD, in particular among general practitioners, access to AATD specialised centres and access to reliable, easy to understand information about living with AATD. Regarding barriers to treatment, participants from countries where augmentation therapy was reimbursed prioritised improving knowledge in AATD, while respondents in non-reimbursed countries regarded access to AATD augmentation therapy and to specialised centres as the most relevant. The main research and management priorities identified by healthcare providers and patients included understanding the natural history of AATD, improving information to physicians, improving access to specialised reference centres, personalising treatment and having equal opportunities for access to existing therapies.
Published: 2020
Full Text: View/download PDF

17. What should be the appropriate minimal duration for patient examination and evaluation in pulmonary outpatient clinics?

Author: Benan Musellim, Sermin Borekci, Gulfidan Uzan, Zafer Hasan Ali Sak, Secil Kepil Ozdemir, Goksel Altinisik, Sinem Agca Altunbey, Nazan Sen, Oguz Kilinc, Arzu Yorgancioglu, and The Duration for Patient Examination Working Group of Turkish Thoracic Society
Subjects: Outpatient clinics, patient examination, suggested duration, Diseases of the circulatory (Cardiovascular) system, RC666-701, Diseases of the respiratory system, RC705-779
Abstract: Introduction: Patient examinations performed in a limited time period may lead to impairment in patient and physician relationship, defective and erroneous diagnosis, inappropriate prescriptions, less common use of preventive medicine practices, poor patient satisfaction, and increased violent acts against health-care staff. Objective: This study aimed to determine the appropriate minimal duration of patient examination in the pulmonary practice. Methods: A total of 49 researchers from ten different study groups of the Turkish Thoracic Society participated in the study. The researchers were asked to examine patients in an almost ideal manner, without time constraint under available conditions. Results: A total of 1680 patient examinations were reviewed. The mean duration of patient examination in ideal conditions was determined to be 20.4 ± 9.6 min. Among all steps of patient examination, the longest time was spent for “taking medical history.” The total time spent for patient examination was statistically significantly longer in the university hospitals than in the governmental hospitals and training and research hospitals (P < 0.001). Among different patient categories, the patients with a chronic disorder presenting for the first time and were referred from primary or secondary to tertiary care for further evaluation have required the longest time for patient examination. Conclusion: According to our study, the appropriate minimal duration for patient examination is 20 min. It has been observed that in university hospitals and in patients with chronic pulmonary diseases, this duration has been increased to above 25 min. The durations in clinical practice should be planned accordingly.
Published: 2017
Full Text: View/download PDF

18. The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis

Author: Jean Bousquet, Mondher Toumi, Bernardo Sousa-Pinto, Josep M. Anto, Anna Bedbrook, Wienczyslawa Czarlewski, Arunas Valiulis, Ignacio J. Ansotegui, Sinthia Bosnic-Anticevich, Luisa Brussino, G. Walter Canonica, Lorenzo Cecchi, Ivan Cherrez-Ojeda, Tomas Chivato, Elísio M. Costa, Alvaro A. Cruz, Stefano Del Giacco, Joao A. Fonseca, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Marek Jutel, Igor Kaidashev, Ludger Klimek, Violeta Kvedariene, Piotr Kuna, Désirée E. Larenas-Linnemann, Brian Lipworth, Mario Morais-Almeida, Joaquim Mullol, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham-Thi, Frederico S. Regateiro, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Luis Taborda-Barata, Maria Teresa Ventura, Arzu Yorgancioglu, Mihaela Zidarn, and Torsten Zuberbier
Subjects: Treatment, Value-added medicine, Allergic rhinitis, MASK-air, Repurposing, Humans, Disease Management, Immunology and Allergy, Rhinitis, Allergic, Mobile Applications, Asthma, Telemedicine
Abstract: Drug repurposing is a major field of value-added medicine. It involves investigating and evaluating existing drugs for new therapeutic purposes that address unmet healthcare needs. Several unmet needs in allergic rhinitis could be improved by drug repurposing. This could be game-changing for disease management. Current medications for allergic rhinitis are centered on continuous long-term treatment, and medication registration is based on randomized controlled trials carried out for a minimum of 14 days with adherence of 70% or greater. A new way of treating allergic rhinitis is to propose as-needed treatment depending on symptoms, rather than classical continuous treatment. This rostrum will discuss existing clinical trials on as-needed treatment for allergic rhinitis and real-world data obtained by the mobile health app MASK-air, which focuses on digitally-enabled, patient-centered care pathways.
Published: 2022

19. Patient-centred digital biomarkers for allergic respiratory diseases and asthma:the ARIA-EAACI approach

Author: Jean Bousquet, Mohamed H. Shamji, Josep M. Anto, Holger J. Schünemann, G. Walter Canonica, Marek Jutel, Stefano Del Giacco, Torsten Zuberbier, Oliver Pfaar, Joao A. Fonseca, Bernardo Sousa‐Pinto, Ludger Klimek, Wienczyslawa Czarlewski, Anna Bedbrook, Rita Amaral, Ignacio J. Ansotegui, Sinthia Bosnic‐Anticevich, Fulvio Braido, Claudia Chaves Loureiro, Bilun Gemicioglu, Tari Haahtela, Marek Kulus, Piotr Kuna, Maciej Kupczyk, Paolo M. Matricardi, Frederico S. Regateiro, Boleslaw Samolinski, Mikhail Sofiev, Sanna Toppila‐Salmi, Arunas Valiulis, Maria Teresa Ventura, Cristina Barbara, Karl C. Bergmann, Michael Bewick, Hubert Blain, Matteo Bonini, Louis‐Philippe Boulet, Rodolphe Bourret, Guy Brusselle, Luisa Brussino, Roland Buhl, Victoria Cardona, Thomas Casale, Lorenzo Cecchi, Denis Charpin, Ivan Cherrez‐Ojeda, Derek K. Chu, Cemal Cingi, Elisio M. Costa, Alvaro A. Cruz, Philippe Devillier, Stephanie Dramburg, Wytske J. Fokkens, Maia Gotua, Enrico Heffler, Zhanat Ispayeva, Juan Carlos Ivancevich, Guy Joos, Igor Kaidashev, Helga Kraxner, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Daniel Laune, Olga Lourenço, Renaud Louis, Mika Makela, Michael Makris, Marcus Maurer, Erik Melén, Yann Micheli, Mario Morais‐Almeida, Joaquim Mullol, Marek Niedoszytko, Robyn O’Hehir, Yoshitaka Okamoto, Heidi Olze, Nikolaos G. Papadopoulos, Alberto Papi, Vincenzo Patella, Benoit Pétré, Nhân Pham‐Thi, Francesca Puggioni, Santiago Quirce, Nicolas Roche, Philip W. Rouadi, Ana Sá‐Sousa, Hironori Sagara, Joaquin Sastre, Nicola Scichilone, Aziz Sheikh, Milan Sova, Charlotte Suppli Ulrik, Luis Taborda‐Barata, Ana Todo‐Bom, Maria J. Torres, Ioanna Tsiligianni, Omar S. Usmani, Erkka Valovirta, Tuula Vasankari, Rafael José Vieira, Dana Wallace, Susan Waserman, Mihaela Zidarn, Arzu Yorgancioglu, Luo Zhang, Tomas Chivato, and Markus Ollert
Subjects: Immunology, Immunology and Allergy
Abstract: Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.
Published: 2023

20. Development and validation of combined symptom-medication scores for allergic rhinitis*

Author: Bernardo Sousa‐Pinto, Luís Filipe Azevedo, Marek Jutel, Ioana Agache, G. Walter Canonica, Wienczyslawa Czarlewski, Nikolaos G. Papadopoulos, Karl‐Christian Bergmann, Philippe Devillier, Daniel Laune, Ludger Klimek, Aram Anto, Josep M. Anto, Patrik Eklund, Rute Almeida, Anna Bedbrook, Sinthia Bosnic‐Anticevich, Helen A. Brough, Luisa Brussino, Victoria Cardona, Thomas Casale, Lorenzo Cecchi, Denis Charpin, Tomás Chivato, Elisio M. Costa, Alvaro A. Cruz, Stephanie Dramburg, Stephen R. Durham, Giulia De Feo, Roy Gerth van Wijk, Wystke J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Maddalena Illario, Juan Carlos Ivancevich, Violeta Kvedariene, Piotr Kuna, Désirée E. Larenas‐Linnemann, Michael Makris, Eve Mathieu‐Dupas, Erik Melén, Mario Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Kari C. Nadeau, Nhân Pham‐Thi, Robyn O’Hehir, Frederico S. Regateiro, Sietze Reitsma, Boleslaw Samolinski, Aziz Sheikh, Cristiana Stellato, Ana Todo‐Bom, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Antonio Valero, Arunas Valiulis, Maria Teresa Ventura, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Govert De Vries, Michiel van Eerd, Petra Zieglmayer, Torsten Zuberbier, Oliver Pfaar, João Almeida Fonseca, Jean Bousquet, Internal Medicine, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Ear, Nose and Throat, AII - Inflammatory diseases, Publica, Sousa-Pinto, B., Azevedo, L. F., Jutel, M., Agache, I., Canonica, G. W., Czarlewski, W., Papadopoulos, N. G., Bergmann, K. -C., Devillier, P., Laune, D., Klimek, L., Anto, A., Anto, J. M., Eklund, P., Almeida, R., Bedbrook, A., Bosnic-Anticevich, S., Brough, H. A., Brussino, L., Cardona, V., Casale, T., Cecchi, L., Charpin, D., Chivato, T., Costa, E. M., Cruz, A. A., Dramburg, S., Durham, S. R., De Feo, G., Gerth van Wijk, R., Fokkens, W. J., Gemicioglu, B., Haahtela, T., Illario, M., Ivancevich, J. C., Kvedariene, V., Kuna, P., Larenas-Linnemann, D. E., Makris, M., Mathieu-Dupas, E., Melen, E., Morais-Almeida, M., Mosges, R., Mullol, J., Nadeau, K. C., Pham-Thi, N., O'Hehir, R., Regateiro, F. S., Reitsma, S., Samolinski, B., Sheikh, A., Stellato, Cristiana, Todo-Bom, A., Tomazic, P. V., Toppila-Salmi, S., Valero, A., Valiulis, A., Ventura, M. T., Wallace, D., Waserman, S., Yorgancioglu, A., De Vries, G., van Eerd, M., Zieglmayer, P., Zuberbier, T., Pfaar, O., Almeida Fonseca, J., and Bousquet, J.
Subjects: Work, medication score, quality-of-life, rhinitis, symptom score, work, Respiratory Medicine and Allergy, Immunology, QUESTIONNAIRE, RESPONSIVENESS, Humans, Immunology and Allergy, IMMUNOTHERAPY, VALIDITY, Lungmedicin och allergi, Rhinitis, Medication score, EQ-5D, Reproducibility of Results, IMPAIRMENT, Rhinitis, Allergic, WORK PRODUCTIVITY, Symptom score, rhiniti, TRIALS, 3121 General medicine, internal medicine and other clinical medicine, RELIABILITY, Quality of Life, ASTHMA, Quality-of-life, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract: Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air®, and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.
Published: 2022

21. Economic burden of short-acting beta-2 agonist (SABA) overuse among asthma patients in Türkiye: a cost analysis with respect to the updated GINA treatment recommendations

Author: Arzu Yorgancıoğlu, Kurtuluş Aksu, Ceyhun Cura, Yiğit Yaman, Melda Dinç, Simten Malhan, and the SABINA Türkiye Study Group
Subjects: Adult asthma, Asthma severity, GINA updates, SABA overuse, Cost analysis, Cost burden, Diseases of the respiratory system, RC705-779
Abstract: Abstract Background This cost of illness study aimed to determine economic burden of short-acting β2-agonist (SABA) overuse in Türkiye from payer perspective with respect to the updated GINA 2022 treatment recommendations. Methods A total of 3,034,879 asthma patients comprised the study population, via estimations extrapolated from the Türkiye arm of the global SABINA III study. The economic burden (costs related to the drug use and severe exacerbations) was compared in subgroups of overall (≥ 0 canisters/year) vs. GINA-recommended (0–2 canisters/year, hypothetical population) SABA use and in subgroups of appropriate use (0–2 canisters/year, real population) vs. overuse (≥ 3 canisters/year) of SABA with extrapolation of SABINA Türkiye data to the Türkiye asthma population. Results Recommended SABA use was predicted to prevent 127,505 of 157,512 severe exacerbations per year in mild asthma patients and 2,668,916 of 3,262,800 severe exacerbations per year in moderate-severe asthma patients. Annual cost burden of not applying recommended SABA use (overall [≥ 0 canisters/year] vs. GINA-recommended [0–2 canisters/year] SABA use) in mild asthma and moderate-severe asthma patients was calculated to be €20.43 million and €427.65 million in terms of severe exacerbations, and to be €829,352 and €7.20 million in terms of drug costs, respectively. The total annual economic burden arising from not applying recommended SABA use was estimated to be €456.11 million. Appropriate use (0–2 canisters/year) vs. overuse (≥ 3 canisters/year) of SABA was associated with decreased frequency of severe exacerbations per year in mild asthma (from 129,878 to 27,634) and moderate-severe asthma (from 2,834,611 to 428,189) patients. SABA overuse in mild and moderate-severe asthma patients was estimated to yield an additional annual cost of €16.38 million and €385.59 million, respectively in terms of severe exacerbations, and a total €11.30 million additional drug cost. The overall annual economic burden arising from SABA overuse was estimated to be €413.27 million. Conclusions The estimated annual total economic burden arising from not applying recommended SABA use (€456.11 million) and SABA overuse (€413.27 million) with respect to the updated GINA 2022 treatment recommendations indicates the substantial cost burden of SABA overuse to the Turkish National Health System, corresponding up to 26% of the total direct cost of asthma reported in our country.
Published: 2024
Full Text: View/download PDF

22. Tobacco and COPD: presenting the World Health Organization (WHO) Tobacco Knowledge Summary

Author: Wenying Lu, Rebekka Aarsand, Kerstin Schotte, Jing Han, Elizaveta Lebedeva, Elena Tsoy, Nino Maglakelidze, Joan B Soriano, Werner Bill, David M G Halpin, M. Patricia Rivera, Kwun M Fong, Hasmeena Kathuria, Arzu Yorgancıoğlu, Monika Gappa, David CL Lam, Sarah Rylance, and Sukhwinder Singh Sohal
Subjects: Chronic obstructive pulmonary disease, Smoking, Tobacco control, Smoking cessation, Diseases of the respiratory system, RC705-779
Abstract: Abstract The WHO recently published a Tobacco Knowledge Summary (TKS) synthesizing current evidence on tobacco and COPD, aiming to raise awareness among a broad audience of health care professionals. Furthermore, it can be used as an advocacy tool in the fight for tobacco control and prevention of tobacco-related disease. This article builds on the evidence presented in the TKS, with a greater level of detail intended for a lung-specialist audience. Pulmonologists have a vital role to play in advocating for the health of their patients and the wider population by sharing five key messages: (1) Smoking is the leading cause of COPD in high-income countries, contributing to approximately 70% of cases. Quitting tobacco is an essential step toward better lung health. (2) People with COPD face a significantly higher risk of developing lung cancer. Smoking cessation is a powerful measure to reduce cancer risk. (3) Cardiovascular disease, lung cancer and type-2 diabetes are common comorbidities in people with COPD. Quitting smoking not only improves COPD management, but also reduces the risk of developing these coexisting conditions. (4) Tobacco smoke also significantly impacts children’s lung growth and development, increasing the risk of respiratory infections, asthma and up to ten other conditions, and COPD later in life. Governments should implement effective tobacco control measures to protect vulnerable populations. (5) The tobacco industry’s aggressive strategies in the marketing of nicotine delivery systems and all tobacco products specifically target children, adolescents, and young adults. Protecting our youth from these harmful tactics is a top priority.
Published: 2024
Full Text: View/download PDF

23. Asthma in the digital world

Author: Jean Bousquet, Bernardo Sousa-Pinto, Francesca Puggioni, Aram Anto, Fabio Balli, Thomas Casale, Wienczyslawa Czarlewski, Anna Bedbrook, Luisa Brussino, Mina Gaga, Bilun Gemicioglu, Ludger Klimek, Violeta Kvedariene, Renaud Louis, Joaquin Sastre, Nicola Scichilone, Arunas Valiulis, Eleptherios Zervas, Arzu Yorgancioglu, Torsten Zuberbier, Josep M Anto, G Walter Canonica, and Joao A Fonseca
Published: 2023

24. Picturing asthma in Turkey: results from the Turkish adult asthma registry

Author: Gulfem Elif Celik, Omur Aydin, Derya Gokmen, Gozde Koycu Buhari, Zeynep Celebi Sozener, Bilun Gemicioglu, Ismet Bulut, Sengul Beyaz, Cihan Orcen, Secil Kepil Ozdemir, Metin Keren, Ebru Damadoglu, Tugce Yakut, Ayse Fusun Kalpaklioglu, Ayse Baccioglu, Sumeyra Alan Yalim, Insu Yilmaz, Ilkay Koca Kalkan, Mehmet Atilla Uysal, Elif Yelda Ozgun Niksarlioglu, Ali Fuat Kalyoncu, Gul Karakaya, Muge Erbay, Sibel Nayci, Fatma Merve Tepetam, Asli Akkor Gelincik, Hulya Dirol, Ozlem Goksel, Selen Karaoglanoglu, Ferda Oner Erkekol, Sacide Rana Isik, Fusun Yildiz, Yasemin Yavuz, Dilek Karadogan, Nurgul Bozkurt, Ummuhan Seker, Ipek Kivilcim Oguzulgen, Ilknur Basyigit, Serap Argun Baris, Elif Yilmazel Ucar, Tuba Erdogan, Mehmet Polatli, Dane Ediger, Fatma Esra Gunaydin, Murat Turk, Leyla Pur, Zeynep Yegin Katran, Yonca Sekibag, Enes Furkan Aykac, Dilsad Mungan, Ozcan Gul, Ali Cengiz, Bulent Akkurt, Seyma Ozden, Semra Demir, Derya Unal, Ayse Feyza Aslan, Ali Can, Reyhan Gumusburun, Gulhan Bogatekin, Hatice Serpil Akten, Sinem Inan, Munevver Erdinc, Aliye Candan Ogus, Murat Kavas, Demet Polat Yulug, Mehmet Erdem Cakmak, Saltuk Bugra Kaya, Gulistan Alpagat, Eylem Sercan Ozgur, Oguz Uzun, Sule Tas Gulen, Gulseren Pekbak, Deniz Kizilirmak, Yavuz Havlucu, Halil Donmez, Bahar Arslan, Gulden Pacaci Cetin, Sadan Soyyigit, Bilge Yilmaz Kara, Gulden Pasaoglu Karakis, Adile Berna Dursun, Resat Kendirlinan, Ayse Bilge Ozturk, Can Sevinc, Gokcen Omeroglu Simsek, Oznur Abadoglu, Pamir Cerci, Taskin Yucel, Irfan Yorulmaz, Zahide Ciler Tezcaner, Emel Cadalli Tatar, Ahmet Emre Suslu, Serdar Ozer, Engin Dursun, and Arzu Yorgancioglu
Subjects: Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health, Immunology and Allergy
Abstract: Introduction: National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry for patients with asthma aiming to take a snapshot of our patients, thereby assigning the unmet needs and niche areas of intervention. Methods: Case entries were performed between March 2018 and March 2022. A web-based application was used to record data. Study outcomes were demographic features, disease characteristics, asthma control levels, and phenotypes. Results: The registry included 2053 patients from 36 study centers in Turkey. Female subjects dominated the group (n = 1535, 74.8%). The majority of the patients had allergic (n = 1158, 65.3%) and eosinophilic (n = 1174, 57.2%) asthma. Six hundred nineteen (32.2%) of the patients had obese asthma. Severe asthma existed in 670 (32.6%) patients. Majority of cases were on step 3–5 treatment (n: 1525; 88.1%). Uncontrolled asthma was associated with low educational level, severe asthma attacks in the last year, low FEV1, existence of chronic rhinosinusitis and living in particular regions. Conclusion: The picture of this registry showed a dominancy of middle-aged obese women with moderate-to-severe asthma. We also determined particular strategic targets such as low educational level, severe asthma attacks, low FEV1, and chronic rhinosinusitis to decrease uncontrolled asthma in our country. Moreover, some regional strategies may also be needed as uncontrolled asthma is higher in certain regions. We believe that these data will guide authorities to reestablish national asthma programs to improve asthma service delivery.
Published: 2023

25. Contributors

Author: Aram Anto, Josep M Anto, Fabio Balli, Annabelle Bedard, Anna Bedbrook, Jean Bousquet, Luisa Brussino, Pierre-Régis Burgel, Emilie Burte, Carlos A. Camargo, Jr., G Walter Canonica, Tara F. Carr, Thomas Casale, Lidia Casas, Guillaume Chassagnon, Wienczyslawa Czarlewski, Shyamali C. Dharmage, Orianne Dumas, Joao A Fonseca, Mina Gaga, Bilun Gemicioglu, Sven Günther, Stéfanie Habib, Kohei Hasegawa, Joachim Heinrich, N. Sabrina Idrose, Bénédicte Jacquemin, Ludger Klimek, Violeta Kvedariene, Bénédicte Leynaert, Zhen Li, Renaud Louis, Clémence Martin, Andréanne Morin, Nicole Le Moual, Rachel Nadif, Hiroyuki Nagase, Carole Ober, Jean Pastré, Sanjay B. Patel, Francesca Puggioni, Francisco Gómez Real, Nicolas Roche, Joaquin Sastre, Marine Savouré, Nathan Schoettler, Nicola Scichilone, Bernardo Sousa-Pinto, Maho Suzukawa, Laura Toivonen, Arunas Valiulis, Raphaëlle Varraso, Arzu Yorgancioglu, Eleptherios Zervas, and Torsten Zuberbier
Published: 2023

26. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author: Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology
Subjects: Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract: Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion
Published: 2021

27. Cut-off values of MASK-air® Patient-Reported Outcome Measures (PROMs)

Author: Bernardo, Sousa-Pinto, Ana, Sá-Sousa, Rafael José, Vieira, Rita, Amaral, Ana Margarida, Pereira, Josep M, Anto, Ludger, Klimek, Wienczyslawa, Czarlewski, Joaquim, Mullol, Oliver, Pfaar, Anna, Bedbrook, Luisa, Brussino, Violeta, Kvedariene, Desirée E, Larenas-Linnemann, Yoshitaka, Okamoto, Maria Teresa, Ventura, Ignacio J, Ansotegui, Sinthia, Bosnic-Anticevich, G Walter, Canonica, Victoria, Cardona, Lorenzo, Cecchi, Tomas, Chivato, Cemal, Cingi, Elísio M, Costa, Alvaro A, Cruz, Stefano, Del Giacco, Philippe, Devillier, Wytske J, Fokkens, Bilun, Gemicioglu, Tari, Haahtela, Juan Carlos, Ivancevich, Piotr, Kuna, Igor, Kaidashev, Helga, Kraxner, Daniel, Laune, Renaud, Louis, Michael, Makris, Riccardo, Monti, Mario, Morais-Almeida, Ralph, Mösges, Marek, Niedoszytko, Nikolaos G, Papadopoulos, Vincenzo, Patella, Nhân, Pham-Thi, Frederico S, Regateiro, Sietze, Reitsma, Philip W, Rouadi, Boleslaw, Samolinski, Aziz, Sheikh, Milan, Sova, Luis, Taborda-Barata, Sanna, Toppila-Salmi, Joaquin, Sastre, Ioanna, Tsiligianni, Arunas, Valiulis, Arzu, Yorgancioglu, Mihaela, Zidarn, Torsten, Zuberbier, Joao A, Fonseca, and Jean, Bousquet
Abstract: In clinical and epidemiological studies, cut-offs of Patient-Reported Outcome Measures (PROMs) can be used to classify patients into groups of statistical and clinical relevance. However, visual analog scale (VAS) cut-offs in MASK-air® have not been tested.To calculate cut-offs for VAS global, nasal, ocular, and asthma symptoms.In a cross-sectional study design of all MASK-air® participants, we compared (i) approaches based on the percentiles (tertiles or quartiles) of VAS distributions, and (ii) data-driven approaches based on clusters of data from two comparators (VAS work and VAS sleep). We then performed sensitivity analyses for individual countries and for VAS levels corresponding to full allergy control. Finally, we tested the different approaches using MASK-air® real-world cross-sectional and longitudinal data to assess the most relevant cut-offs.We assessed 395,223 days from 23,201 MASK-air® users with self-reported allergic rhinitis. The percentile-oriented approach resulted in lower cut-off values than the data-driven approach. We obtained consistent results in the data-driven approach. Following the latter, the proposed cut-off differentiating "controlled" and "partly-controlled" patients was similar to the cut-off value which had been arbitrarily used (20/100). However, a lower cut-off was obtained to differentiate between "partly-controlled" and "uncontrolled" patients (35 versus the arbitrarily-used value of 50/100).Using a data-driven approach, we were able to define cut-off values for MASK-air® VASs on allergy and asthma symptoms. This may allow for a better classification of rhinitis and asthma patients according to different levels of control, supporting improved disease management.
Published: 2022

28. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference

Author: Bernardo Sousa‐Pinto, Holger J. Schünemann, Ana Sá‐Sousa, Rafael José Vieira, Rita Amaral, Josep M. Anto, Ludger Klimek, Wienczyslawa Czarlewski, Joaquim Mullol, Oliver Pfaar, Anna Bedbrook, Luisa Brussino, Violeta Kvedariene, Desirée Larenas‐Linnemann, Yoshitaka Okamoto, Maria Teresa Ventura, Ioana Agache, Ignacio J. Ansotegui, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, Jan Brozek, G. Walter Canonica, Victoria Cardona, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Tomas Chivato, Derek K. Chu, Cemal Cingi, Elísio M. Costa, Alvaro A. Cruz, Stefano Del Giacco, Philippe Devillier, Patrik Eklund, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Zhanat Ispayeva, Marek Jutel, Piotr Kuna, Igor Kaidashev, Musa Khaitov, Helga Kraxner, Daniel Laune, Brian Lipworth, Renaud Louis, Michael Makris, Riccardo Monti, Mario Morais‐Almeida, Ralph Mösges, Marek Niedoszytko, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Milan Sova, Ana Todo‐Bom, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Olivier Vandenplas, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, Joao A. Fonseca, Jean Bousquet, Ear, Nose and Throat, AII - Inflammatory diseases, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Comprehensive Health Research Centre (CHRC) - pólo NMS, NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Publica
Subjects: allergic rhinitis, real-world data, allergen immunotherapy, co-medication, multivariable mixed-effects model, Immunology, Allergen immunotherapy, Rhinitis, Allergic, Adrenal Cortex Hormones, Desensitization, Immunologic, HDE ALER, Immunology and Allergy, Fluticasone, Humans, Rhinitis
Abstract: Funding Information: IA reports personal fees from Roxall, Menarini, UCB, Faes Farma, Sanofi, Bial, Amgen, Abbott, Bayer, Organon. SBA reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. JB reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, personal fees from Purina, other from MASK‐air. VC reports personal fees from Thermofisher. PCM reports personal fees from Abbvie, AZ, Bial, GSK, Mylan, Medinfar, Novartis, Sanofi. LC reports personal fees from Malesci, Menarini, Astra Zeneca, Novartis. AC reports grants and personal fees from Astrazeneca, GSK, Sanofi, personal fees from Boehringer‐Ingelheim, Chiesi, Glenmark, Novartis, personal fees from Mylan, Abdi‐Ibrahim. PD reports personal fees and non‐financial support from Stallergenes Greer, ALK‐Abello, Astra Zeneca, CHIESI, MYLAN/Meda Pharma, Novartis, GlaxoSmithKline, Sanofi, IQVIA personal fees from MENARINI. JAFonseca reports participation in SME that has mHealth technologies for patients with asthma. JCI reports personal fees from Abbott Ecuador, Bago Bolivia, Faes Farma, Laboratorios Casasco, Sanofi. LK reports grants and personal fees from Allergopharma, LETI Pharma,MEDA/Mylan, Sanofi, personal fees from HAL Allergie, Allergy Therapeut., Cassella med, grants from ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotk, and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, EAACI. VK reports other from Norameda, BerlinCHemie Menarini. PK reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, Boehringer Ingelheim, Chiesi, GSK, Novartis, Polpharma. DLL reports personal fees from Allakos, Amstrong, Astrazeneca, Chiesi, DBV Technologies, Grunenthal, GSK, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, Gossamer, Carnot, grants from Sanofi, Astrazeneca, Novartis, Circassia, UCB, GSK, Purina institute, Abvvie, Lilly, Pfizer. BL reports grants and personal fees from Meda, personal fees from Glenamrk. RL reports grants and personal fees from GSK, AZ, Chiesi, personal fees from Novartis, Sanofi. MM reports personal fees from Novartis, Gsk, Menarini, Az, Chiesi, Sanofi, Pfizer. RM reports personal fees from Angelini Pharma ALK, Allergopharma, Allergy Therapeutics, Friulchem, Hexal, Servier, Klosterfrau, Bayer, FAES, GSK, MSD, Johnson&Johnson, Meda, Stada, UCB, Nuvo, Menarini, Mundipharma, Pohl‐Boskamp, Laboratoire de la Mer, Sidroga, Lek, PRO‐AdWise, grants and personal fees from Bencard, Stallergenes, Ursapharm, HAL BV, grants from Leti, Optima, BitopAG, Hulka, Inmunotek, Cassella‐med GmbH & Co. KG, ASIT biotech, grants, personal fees and non‐financial support from Lofarma, non‐financial support from Roxall, Atmos, Bionorica, Otonomy, Ferrero, personal fees and non‐financial support from Novartis. OP reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, Anergis S.A., GlaxoSmithKline, personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, Paul‐Martini‐Stiftung (PMS), Regeneron Pharmaceuticals Inc., RG Aerztefortbildung, Institut für Disease Management, Springer GmbH, AstraZeneca, IQVIA Commercial, Ingress Health, grants from Pohl‐Boskamp, Inmunotek S.L., Biomay, Circassia. NGPapadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. ATB reports personal fees from AstraZeneca, GSK, Novartis, IQVIA/Abbvie, Mylan, Bial, Leti, grants and personal fees from Teva. STS reports personal fees from ERT, Roche products, Novartis, Sanofi Pharma, AstraZeneca, ALK‐ Abelló grants from Glaxo Smith Kline. IT reports grants from GSK, Boehringer Ingelheim, AZ, personal fees from Novartis, Astra Zeneca, Chiesi, TZ reports Organizational affiliations: Committee member: WHO‐Initiative “Allergic Rhinitis and Its Impact on Asthma” (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF). President: Global Allergy and Asthma European Network (GA2LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). Funding Information: MASK‐air® has been supported by EU grants (POLLAR, EIT Health; Structural and Development Funds, Twinning, EIP on AHA and H2020) and educational grants from Mylan‐Viatris, ALK, GSK, Novartis and Uriach 1 1 Publisher Copyright: © 2022 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. Background: Different treatments exist for allergic rhinitis (AR), including pharmacotherapy and allergen immunotherapy (AIT), but they have not been compared using direct patient data (i.e., “real-world data”). We aimed to compare AR pharmacological treatments on (i) daily symptoms, (ii) frequency of use in co-medication, (iii) visual analogue scales (VASs) on allergy symptom control considering the minimal important difference (MID) and (iv) the effect of AIT. Methods: We assessed the MASK-air® app data (May 2015–December 2020) by users self-reporting AR (16–90 years). We compared eight AR medication schemes on reported VAS of allergy symptoms, clustering data by the patient and controlling for confounding factors. We compared (i) allergy symptoms between patients with and without AIT and (ii) different drug classes used in co-medication. Results: We analysed 269,837 days from 10,860 users. Most days (52.7%) involved medication use. Median VAS levels were significantly higher in co-medication than in monotherapy (including the fixed combination azelastine-fluticasone) schemes. In adjusted models, azelastine-fluticasone was associated with lower average VAS global allergy symptoms than all other medication schemes, while the contrary was observed for oral corticosteroids. AIT was associated with a decrease in allergy symptoms in some medication schemes. A difference larger than the MID compared to no treatment was observed for oral steroids. Azelastine-fluticasone was the drug class with the lowest chance of being used in co-medication (adjusted OR = 0.75; 95% CI = 0.71–0.80). Conclusion: Median VAS levels were higher in co-medication than in monotherapy. Patients with more severe symptoms report a higher treatment, which is currently not reflected in guidelines. publishersversion published
Published: 2022

29. Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement

Author: Erik Melén, Edward F Knol, Karin Hoffmann-Sommergruber, N. Khaltaev, Bolesław Samoliński, Cezmi A. Akdis, Claus Bachert, Hui Du, Sinthia Bosnic-Anticevich, Maria Teresa Ventura, Ruby Pawankar, Mohamed H. Shamji, Mübeccel Akdis, Ken Ohta, Joaquim Mullol, Jean Bousquet, Robert M. Naclerio, Ioana Agache, Tari Haahtela, Arunas Valiulis, Sanna Toppila-Salmi, I. J. Ansotegui, J. C. Ivancevich, Oliver Pfaar, Giorgio Walter Canonica, Gabrielle L. Onorato, Ya-dong Gao, Alvaro A. Cruz, Anna Bedbrook, Stefano Del Giacco, Yoshitaka Okamoto, Marek Jutel, P. M. Matricardi, Nikos G Papadopoulos, Wiencyslawa Czarlewski, João Fonseca, D. Larenas-Linnemann, Piotr Kuna, Tomas Chivato, Arzu Yorgancioglu, Jürgen Schwarze, Torsten Zuberbier, Ludger Klimek, Liam O'Mahony, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Clinical Immunology, Wrocław Medical University, ALL-MED Medical Research Institute, Poland, Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland, Universitätsmedizin Berlin, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, CharitéHumboldt-Universität zu BerlinBerlin, Germany, University Hospital, Montpellier, France, MACVIA-France, Montpellier, France, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, Transylvania University BrasovBrasov, Romania, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, NSW, Australia, Personalized Medicine Clinic Asthma & Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milan, Italy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Rozzano, MI, Italy, School of Medicine, University CEU San PabloMadrid, Spain, ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil, Medical Consulting Czarlewski, Montpellier, France, Department of Medical Sciences and Public Health and Unit of Allergy and Clinical Immunology, University Hospital 'Duilio Casula', University of Cagliari, Cagliari, Italy, Department of Respiratory Medicine, Wuhan Children's Hospital, Tongji Medical College, University of Science and Technology, Wuhan, Hubei, China, Center for research in health technologies and information systems- CINTESIS, Universidade do PortoPorto, Portugal, Allergy Unit, Instituto CUF Porto e Hospital CUF PortoPorto, Portugal, Health Information and Decision Sciences Department - CIDES, Faculdade de Medicina, Universidade do PortoPorto, Portugal, Faculdade de Medicina da Universidade do PortoPorto, Portugal, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Department of Pathophysiology and Allergy Research, Medical University of ViennaVienna, Austria, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Aires, Argentina, Geneva, Switzerland, Departments of Immunology and Dermatology/Allergology, University Medical CenterUtrecht, Netherlands, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and HospitalMéxico City, Mexico, Institute of Environmental Medicine, Karolinska Institutet and Sachs' Children's HospitalStockholm, Sweden, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Johns Hopkins School of Medicine, Baltimore, MD, United States, National Hospital Organization, Tokyo National HospitalTokyo, Japan, Dept of Otorhinolaryngology, Chiba University HospitalChiba, Japan, Departments of Medicine and Microbiology, University College Cork, Cork, Ireland, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of ManchesterManchester, United Kingdom, Department of Pediatrics, Nippon Medical SchoolTokyo, Japan, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Germany, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland, Centre for Inflammation Research, Child Life and Health, University of Edinburgh, Edinburgh, United Kingdom, Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Inflammation, Repair and Development, National Heart and Lung Institute, Imperial College London. Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom, University of Bari Medical School, Unit of Geriatric ImmunoallergologyBari, Italy, Vilnius University, Faculty of Medicine, Institute of Clinical Medicine &, Institute of Health SciencesVilnius, Lithuania, European Academy of Paediatrics, Brussels, Belgium, Celal Bayar University, Department of PulmonologyManisa, Turkey, Charité - Universitätsmedizin BerlinBerlin, Germany, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and AllergyBerlin, Germany, Klimek, Ludger, Jutel, Marek, Akdis, Cezmi, Bousquet, Jean, Akdis, Mübeccel, Bachert, Clau, Agache, Ioana, Ansotegui, Ignacio, Bedbrook, Anna, Bosnic-Anticevich, Sinthia, Canonica, Giorgio W, Chivato, Toma, Cruz, Alvaro A, Czarlewski, Wiencyslawa, Giacco, Stefano Del, Du, Hui, Fonseca, Joao A, Gao, Yadong, Haahtela, Tari, Hoffmann-Sommergruber, Karin, Ivancevich, Juan-Carlo, Iaccarino, Guido, Khaltaev, Nikolai, Knol, Edward F, Kuna, Piotr, Larenas-Linnemann, Desiree, Melen, Erik, Mullol, Joaquim, Naclerio, Robert, Ohta, Ken, Okamoto, Yoshitaka, O'Mahony, Liam, Onorato, Gabrielle L, Papadopoulos, Nikos G, Pawankar, Ruby, Pfaar, Oliver, Samolinski, Boleslaw, Schwarze, Jurgen, Toppila-Salmi, Sanna, Shamji, Mohamed H, Ventura, Maria Teresa, Valiulis, Aruna, Yorgancioglu, Arzu, Matricardi, Paolo, Zuberbier, Torsten, Department of Dermatology, Allergology and Venereology, HUS Inflammation Center, and Department of Pathology
Subjects: 0301 basic medicine, Allergy, Eaaci Position Paper, CD8-Positive T-Lymphocytes, Social life, 0302 clinical medicine, clinical immunotherapy, Pandemic, Immunology and Allergy, Infection control, AIT, Treatment options, 3. Good health, Coronavirus Infections, Allergen immunotherapy, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Immunology, Eaaci Position Papers, MECHANISMS, Betacoronavirus, 03 medical and health sciences, Allergists, Th2 Cells, VACCINES, allergy treatment, medicine, VENOM ALLERGY, Humans, Intensive care medicine, Pandemics, Infection Control, Sublingual Immunotherapy, immunotherapy vaccines and mechanisms, SARS-CoV-2, business.industry, COVID-19, Immunoglobulin E, medicine.disease, Rhinitis, Allergic, Asthma, Allergen-specific immunotherapy, Coronavirus, Eosinophils, 030104 developmental biology, Immunoglobulin M, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, business
Abstract: The current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
Published: 2020

30. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air

Author: Bernardo, Sousa-Pinto, Ana, Sá-Sousa, Rafael José, Vieira, Rita, Amaral, Ludger, Klimek, Wienczyslawa, Czarlewski, Josep M, Antó, Oliver, Pfaar, Anna, Bedbrook, Violeta, Kvedariene, Maria Teresa, Ventura, Ignacio J, Ansotegui, Karl-Christian, Bergmann, Luisa, Brussino, G Walter, Canonica, Victoria, Cardona, Pedro, Carreiro-Martins, Tomas, Casale, Lorenzo, Cecchi, Tomás, Chivato, Derek K, Chu, Cemal, Cingi, Elísio M, Costa, Alvaro A, Cruz, Giulia, De Feo, Philippe, Devillier, Wytske J, Fokkens, Mina, Gaga, Bilun, Gemicioğlu, Tari, Haahtela, Juan Carlos, Ivancevich, Zhanat, Ispayeva, Marek, Jutel, Piotr, Kuna, Igor, Kaidashev, Helga, Kraxner, Désirée E, Larenas-Linnemann, Daniel, Laune, Brian, Lipworth, Renaud, Louis, Michael, Makris, Riccardo, Monti, Mario, Morais-Almeida, Ralph, Mösges, Joaquim, Mullol, Mikaëla, Odemyr, Yoshitaka, Okamoto, Nikolaos G, Papadopoulos, Vincenzo, Patella, Nhân, Pham-Thi, Frederico S, Regateiro, Sietze, Reitsma, Philip W, Rouadi, Boleslaw, Samolinski, Milan, Sova, Ana, Todo-Bom, Luis, Taborda-Barata, Peter Valentin, Tomazic, Sanna, Toppila-Salmi, Joaquin, Sastre, Ioanna, Tsiligianni, Arunas, Valiulis, Olivier, Vandenplas, Dana, Wallace, Susan, Waserman, Arzu, Yorgancioglu, Mihaela, Zidarn, Torsten, Zuberbier, João A, Fonseca, and Jean, Bousquet
Subjects: Europe, Habits, Histamine Antagonists, Humans, Rhinitis, Allergic, Rhinitis
Abstract: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data.We analysed 2015-2020 MASK-airWe analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral HAllergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity.
Published: 2022

31. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study

Author: Bernardo Sousa‐Pinto, Holger J. Schünemann, Ana Sá‐Sousa, Rafael José Vieira, Rita Amaral, Josep M. Anto, Ludger Klimek, Wienczyslawa Czarlewski, Joaquim Mullol, Oliver Pfaar, Anna Bedbrook, Luisa Brussino, Violeta Kvedariene, Désirée E. Larenas‐Linnemann, Yoshitaka Okamoto, Maria Teresa Ventura, Ioana Agache, Ignacio J. Ansotegui, Karl C. Bergmann, Sinthia Bosnic‐Anticevich, G. Walter Canonica, Victoria Cardona, Pedro Carreiro‐Martins, Thomas Casale, Lorenzo Cecchi, Tomas Chivato, Derek K. Chu, Cemal Cingi, Elísio M. Costa, Alvaro A. Cruz, Stefano Del Giacco, Philippe Devillier, Patrik Eklund, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Zhanat Ispayeva, Marek Jutel, Piotr Kuna, Igor Kaidashev, Musa Khaitov, Helga Kraxner, Daniel Laune, Brian Lipworth, Renaud Louis, Michael Makris, Riccardo Monti, Mario Morais‐Almeida, Ralph Mösges, Marek Niedoszytko, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham‐Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Milan Sova, Ana Todo‐Bom, Luis Taborda‐Barata, Sanna Toppila‐Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Olivier Vandenplas, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, Joao A. Fonseca, Jean Bousquet, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Ear, Nose and Throat, AII - Inflammatory diseases, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, Helsinki University Hospital Area, and Department of Pathology
Subjects: Patient-reported outcomes, real-world data, Respiratory Medicine and Allergy, Immunology, Oto-rino-laryngologi, Rhinitis* / epidemiology, Real-world data, rhinitis, Otorhinolaryngology, patient-reported outcomes, Surveys and Questionnaires, HDE ALER, 3121 General medicine, internal medicine and other clinical medicine, Humans, Immunology and Allergy, Longitudinal Studies, Mobile health, mobile health, Telemedicine, Lungmedicin och allergi, Rhinitis
Abstract: Data de publicació electrònica: 03-11-2022 Introduction: Data from mHealth apps can provide valuable information on rhinitis control and treatment patterns. However, in MASK-air®, these data have only been analyzed cross-sectionally, without considering the changes of symptoms over time. We analyzed data from MASK-air® longitudinally, clustering weeks according to reported rhinitis symptoms. Methods: We analyzed MASK-air® data, assessing the weeks for which patients had answered a rhinitis daily questionnaire on all 7 days. We firstly used k-means clustering algorithms for longitudinal data to define clusters of weeks according to the trajectories of reported daily rhinitis symptoms. Clustering was applied separately for weeks when medication was reported or not. We compared obtained clusters on symptoms and rhinitis medication patterns. We then used the latent class mixture model to assess the robustness of results. Results: We analyzed 113,239 days (16,177 complete weeks) from 2590 patients (mean age ± SD = 39.1 ± 13.7 years). The first clustering algorithm identified ten clusters among weeks with medication use: seven with low variability in rhinitis control during the week and three with highly-variable control. Clusters with poorly-controlled rhinitis displayed a higher frequency of rhinitis co-medication, a more frequent change of medication schemes and more pronounced seasonal patterns. Six clusters were identified in weeks when no rhinitis medication was used, displaying similar control patterns. The second clustering method provided similar results. Moreover, patients displayed consistent levels of rhinitis control, reporting several weeks with similar levels of control. Conclusions: We identified 16 patterns of weekly rhinitis control. Co-medication and medication change schemes were common in uncontrolled weeks, reinforcing the hypothesis that patients treat themselves according to their symptoms.
Published: 2022

32. Cutoff Values of MASK-air Patient-Reported Outcome Measures

Author: Bernardo Sousa-Pinto, Ana Sá-Sousa, Rafael José Vieira, Rita Amaral, Ana Margarida Pereira, Josep M. Anto, Ludger Klimek, Wienczyslawa Czarlewski, Joaquim Mullol, Oliver Pfaar, Anna Bedbrook, Luisa Brussino, Violeta Kvedariene, Desirée E. Larenas-Linnemann, Yoshitaka Okamoto, Maria Teresa Ventura, Ignacio J. Ansotegui, Sinthia Bosnic-Anticevich, G. Walter Canonica, Victoria Cardona, Lorenzo Cecchi, Tomas Chivato, Cemal Cingi, Elísio M. Costa, Alvaro A. Cruz, Stefano Del Giacco, Philippe Devillier, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Piotr Kuna, Igor Kaidashev, Helga Kraxner, Daniel Laune, Renaud Louis, Michael Makris, Riccardo Monti, Mario Morais-Almeida, Ralph Mösges, Marek Niedoszytko, Nikolaos G. Papadopoulos, Vincenzo Patella, Nhân Pham-Thi, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Milan Sova, Luis Taborda-Barata, Sanna Toppila-Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, Joao A. Fonseca, and Jean Bousquet
Subjects: Asthma, Conjunctivitis, Cutoffs, MASK-air, Rhinitis, Immunology and Allergy
Published: 2022

33. Development and Validation of an Electronic Daily Control Score for Asthma (e-DASTHMA)

Author: Bernardo Sousa-Pinto, Cristina Jácome, Ana Margarida Pereira, Frederico S. Regateiro, Rute Almeida, Wienczyslawa Czarlewski, Marek Kulus, Mohamed Shamji, Louis Philippe Boulet, Matteo Bonini, Luisa Brussino, G. Walter Canonica, Álvaro Cruz, Bilun Gemicioglu, Tari Haahtela, Maciej Kupczyk, Violeta Kvedariene, Desirée Larenas-Linnemann, Renaud Louis, Marek Niedoszytko, Nhân Pham-Thi, Francesca Puggioni, Jan Romantowski, Joaquin Sastre, Nicola Scichilone, Luis Taborda-Barata, Maria Teresa Ventura, Rafael José Vieira, Ioana Agache, Anna Bedbrook, Karl C. Bergmann, Rita Amaral, Luís Filipe Azevedo, Sinthia Bosnic-Anticevich, Guy Brusselle, Roland Buhl, Lorenzo Cecchi, Denis Charpin, Claudia Chaves Loureiro, Frédéric de Blay, Stefano Del Giacco, Philippe Devillier, Ewa Jassem, Guy Joos, Marek Jutel, Ludger Klimek, Piotr Kuna, Daniel Laune, Jorge Luna Pech, Mika Makela, Mario Morais-Almeida, Rachel Nadif, Hugo E. Neffen, Ken Ohta, Nikolaos G. Papadopoulos, Alberto Papi, Benoit Pétré, Oliver Pfaar, Daniela Rivero Yeverino, Carlos Robalo-Cordeiro, Nicolas Roche, Ana Sá-Sousa, Boleslaw Samolinski, Aziz Sheikh, Charlotte Suppli Ulrik, Omar Usmani, Arunas Valiulis, Olivier Vandenplas, Pedro Vieira-Marques, Arzu Yorgancioglu, Torsten Zuberbier, Josep M. Antó, Joao A. Fonseca, and Jean Bousquet
Subjects: History, Polymers and Plastics, Business and International Management, Industrial and Manufacturing Engineering
Published: 2022

34. Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes

Author: Helen K. Reddel, Fanny W.S. Ko, Jiangtao Lin, Aziz Sheikh, Arzu Yorgancioglu, Kevin Mortimer, Roland Buhl, Paulo Márcio Pitrez, Alvaro A. Cruz, Jerry A. Krishnan, Eric D. Bateman, Louise Fleming, Mark L. Levy, Guy Brusselle, Hiromasa Inoue, Liesbeth Duijts, Jeffrey M. Drazen, J Mark FitzGerald, Louis-Philippe Boulet, Christopher E. Brightling, Leonard B. Bacharier, Epidemiology, Pulmonary Medicine, Pediatrics, Reddel, Helen K [0000-0002-6695-6350], Bacharier, Leonard B [0000-0003-0432-2704], Bateman, Eric D [0000-0002-5064-5849], Brightling, Christopher E [0000-0002-9345-4903], Brusselle, Guy G [0000-0001-7021-8505], Duijts, Liesbeth [0000-0001-6731-9452], Drazen, Jeffrey M [0000-0003-2715-9890], FitzGerald, J Mark [0000-0002-5367-5226], Fleming, Louise J [0000-0002-7268-7433], Inoue, Hiromasa [0000-0001-8080-3812], Ko, Fanny W [0000-0001-8454-0087], Krishnan, Jerry A [0000-0001-5525-4778], Levy, Mark L [0000-0002-1807-3246], Lin, Jiangtao [0000-0002-0228-572X], Mortimer, Kevin [0000-0002-8118-8871], Pitrez, Paulo M [0000-0001-7319-1133], Sheikh, Aziz [0000-0001-7022-3056], Yorgancioglu, Arzu A [0000-0002-4032-0944], Boulet, Louis-Philippe [0000-0003-3485-9393], and Apollo - University of Cambridge Repository
Subjects: Exacerbation, Respiratory System, INHALED CORTICOSTEROIDS, Critical Care and Intensive Care Medicine, Asthma management, SINGLE-INHALER, DOUBLE-BLIND, Risk Factors, immune system diseases, Adrenal Cortex Hormones, RELIEVER THERAPY, Formoterol Fumarate, Medicine and Health Sciences, Immunology and Allergy, Anti-Asthmatic Agents, Child, 11 Medical and Health Sciences, Lung function, MILD PERSISTENT ASTHMA, Executive summary, Biologic therapies, Combined Modality Therapy, LUNG-FUNCTION, Child, Preschool, Practice Guidelines as Topic, Perspective, Disease Progression, Drug Therapy, Combination, medicine.drug, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, BUDESONIDE/FORMOTEROL MAINTENANCE, Adolescent, Mild asthma, MEDLINE, Inhaled corticosteroids, CONTROLLED-TRIAL, Skills training, GINA Strategy 2021: Executive Summary, BUDESONIDE-FORMOTEROL, Administration, Inhalation, medicine, Humans, asthma prevention, Intensive care medicine, SEVERE EXACERBATIONS, Asthma, asthma diagnosis, business.industry, Patient Acuity, Infant, asthma, medicine.disease, respiratory tract diseases, Self Care, wf_140, Formoterol, wf_100, business, asthma management
Abstract: Funder: Global Initiative for Asthma, The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an annually updated evidence-based strategy for asthma management and prevention, which can be adapted for local circumstances (e.g., medication availability). This article summarizes key recommendations from GINA 2021, and the evidence underpinning recent changes. GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting β2 -agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-needed combination ICS-formoterol reduces severe exacerbations by ≥60% in mild asthma compared with SABA alone, with similar exacerbation, symptom, lung function, and inflammatory outcomes as daily ICS plus as-needed SABA. Key changes in GINA 2021 include division of the treatment figure for adults and adolescents into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: as needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol (maintenance-and-reliever therapy, "MART") in Steps 3-5. Track 2 (alternative) has as-needed SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting β2 -agonist (Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment options are added at Steps 3-4. Across all age groups and levels of severity, regular personalized assessment, treatment of modifiable risk factors, self-management education, skills training, appropriate medication adjustment, and review remain essential to optimize asthma outcomes.
Published: 2021

35. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study

Author: Michael E Wechsler, Andrew Menzies-Gow, Christopher E Brightling, Piotr Kuna, Stephanie Korn, Tobias Welte, Janet M Griffiths, Kinga Sałapa, Åsa Hellqvist, Gun Almqvist, Harbans Lal, Primal Kaur, Tor Skärby, Gene Colice, Victor H Cambursano, Marcelo J Fernandez, Fernando D Scherbovsky, Anahi Yanez, Alberto J Tolcachier, Ana M Stok, Fernando J B Verra, Karin Forster, Mathias Rolke, Andrea Ludwig-Sengpiel, Tibor Schmoller, Olaf Schmidt, Katrin Milger-Kneidinger, Martin Hoffmann, Hilke Temme, Anneliese Linnhoff, Joachim Kirschner, Barbara Rewerska, Ewa Pisarczyk-Bogacka, Sang Haak Lee, Byung Jae Lee, Heung-Woo Park, Jung-Won Park, Sook Young Lee, You Sook Cho, Kwan Ho Lee, Sevim Bavbek, Bilun Gemicioglu, Dane Ediger, Ilkay Koca Kalkan, Ismail Hanta, Arzu Yorgancioglu, Yevgeniya DytyatkovsKa, Yuriy M Mostovoy, Kyrylo Lebed, Oleh Yakovenko, David I Bernstein, Jeffrey P Tillinghast, Loretta Que, Jan Madison, Todd Rambasek, Kartik Shenoy, Charles A Thompson, Christopher M Chappel, Golda Hudes, Ehab Sorial, Shahrukh A Kureishy, Syed M Rehman, Njira Lugogo, Erika G Gonzalez, Fred C Umeh, Eric J Boren, Jason Sigmon, Hummayun Ismail, Arjun Mohan, Sandeep Bansal, and Thomas D Kaelin
Subjects: Pulmonary and Respiratory Medicine, Adult, Eosinophils, Treatment Outcome, Double-Blind Method, Adrenal Cortex Hormones, Humans, Antibodies, Monoclonal, Humanized, Asthma
Abstract: Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin. SOURCE evaluated the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma.We conducted this phase 3, multicentre, randomised, double-blind, placebo-controlled study across 60 sites in seven countries. Participants aged 18-80 years with physician-diagnosed asthma, who had been receiving medium-dose or high-dose inhaled corticosteroids and had at least one asthma exacerbation in the 12 months before screening were eligible. Patients who were receiving medium-dose inhaled corticosteroids must have had their dose increased to a high dose for at least 3 months before screening. After an oral corticosteroid optimisation phase of up to 8 weeks, participants were randomly assigned according to a computer-generated fixed block randomisation sequence to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks during a 48 week treatment period (4 week induction phase, 36 week oral corticosteroid reduction phase, and 8 week maintenance phase). Randomisation was stratified by region. Participants, investigators, and site staff were masked to treatment assignment. The primary endpoint was the categorised percentage reduction from baseline in daily oral corticosteroid dose at week 48 without the loss of asthma control. Efficacy and safety endpoints were assessed in all participants who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT03406078.Between March 5, 2018, and Sept 27, 2019, 150 participants were randomly assigned to receive tezepelumab 210 mg (n=74) or placebo (n=76). The cumulative odds of achieving a category of greater percentage reduction in an oral corticosteroid dose for daily maintenance at week 48 were similar with tezepelumab or placebo in the overall population (odds ratio [OR] 1·28 [95% CI 0·69-2·35], p=0·43; the primary endpoint was not met). The cumulative odds were higher with tezepelumab than with placebo in participants with baseline blood eosinophil counts of at least 150 cells per μL (2·58 [1·16-5·75]), but not in participants with counts below 150 cells per μL (0·40 [0·14-1·13]). Tezepelumab was well tolerated, with no safety concerns identified. 53 (72%) of 74 tezepelumab-assigned participants and 65 (86%) of 76 placebo-assigned participants reported an adverse event. Serious adverse events were reported in 12 (16%) participants in the tezepelumab group and 16 (21%) participants in the placebo group.We did not observe a significant improvement in oral corticosteroid dose reduction with tezepelumab versus placebo in the overall population of this oral corticosteroid-sparing study, although an improvement was observed in participants with baseline blood eosinophil counts of at least 150 cells per μL.AstraZeneca and Amgen.
Published: 2021

36. Academic Productivity of Young People With Allergic Rhinitis: A MASK-air Study

Author: Rafael José Vieira, Nhân Pham-Thi, Josep M. Anto, Wienczyslawa Czarlewski, Ana Sá-Sousa, Rita Amaral, Anna Bedbrook, Sinthia Bosnic-Anticevich, Luisa Brussino, G. Walter Canonica, Lorenzo Cecchi, Alvaro A. Cruz, Wytske J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Juan Carlos Ivancevich, Ludger Klimek, Piotr Kuna, Violeta Kvedariene, Désirée Larenas-Linnemann, Mario Morais-Almeida, Joaquim Mullol, Marek Niedoszytko, Yoshitaka Okamoto, Nikolaos G. Papadopoulos, Vincenzo Patella, Oliver Pfaar, Frederico S. Regateiro, Sietze Reitsma, Philip W. Rouadi, Boleslaw Samolinski, Aziz Sheikh, Luis Taborda-Barata, Sanna Toppila-Salmi, Joaquin Sastre, Ioanna Tsiligianni, Arunas Valiulis, Maria Teresa Ventura, Susan Waserman, Arzu Yorgancioglu, Mihaela Zidarn, Torsten Zuberbier, João A. Fonseca, Jean Bousquet, Bernardo Sousa-Pinto, Publica, Ear, Nose and Throat, and AII - Inflammatory diseases
Subjects: Adolescent, Visual Analog Scale, MASK, Academic productivity, Allergic rhinitis, Mobile health, Real-world data, Efficiency, Rhinitis, Allergic, Surveys and Questionnaires, Quality of Life, Humans, Immunology and Allergy, Rhinitis
Abstract: Background: Several studies have suggested an impact of allergic rhinitis on academic productivity. However, large studies with real-world data (RWD) are not available. Objective: To use RWD to assess the impact of allergic rhinitis on academic performance (measured through a visual analog scale [VAS] education and the Work Productivity and Activity Impairment Questionnaire plus Classroom Impairment Questions: Allergy Specific [WPAI+CIQ:AS] questionnaire), and to identify factors associated with the impact of allergic rhinitis on academic performance. Methods: We assessed data from the MASK-air mHealth app of users aged 13 to 29 years with allergic rhinitis. We assessed the correlation between variables measuring the impact of allergies on academic performance (VAS education, WPAI+CIQ:AS impact of allergy symptoms on academic performance, and WPAI+CIQ:AS percentage of education hours lost due to allergies) and other variables. In addition, we identified factors associated with the impact of allergic symptoms on academic productivity through multivariable mixed models. Results: A total of 13,454 days (from 1970 patients) were studied. VAS education was strongly correlated with the WPAI+CIQ:AS impact of allergy symptoms on academic productivity (Spearman correlation coefficient = 0.71 [95% confidence interval (CI) = 0.58; 0.80]), VAS global allergy symptoms (0.70 [95% CI = 0.68; 0.71]), and VAS nose (0.66 [95% CI = 0.65; 0.68]). In multivariable regression models, immunotherapy showed a strong negative association with VAS education (regression coefficient = -2.32 [95% CI = -4.04; -0.59]). Poor rhinitis control, measured by the combined symptom-medication score, was associated with worse VAS education (regression coefficient = 0.88 [95% CI = 0.88; 0.92]), higher impact on academic productivity (regression coefficient = 0.69 [95% CI = 0.49; 0.90]), and higher percentage of missed education hours due to allergy (regression coefficient = 0.44 [95% CI = 0.25; 0.63]). Conclusion: Allergy symptoms and worse rhinitis control are associated with worse academic productivity, whereas immunotherapy is associated with higher productivity.
Published: 2022

37. Does one year change in quality of life predict the mortality in patients with chronic obstructive pulmonary disease?—Prospective cohort study

Author: Aysin Sakar Coskun, Pinar Celik, Yavuz Havlucu, and Arzu Yorgancioglu
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, education.field_of_study, COPD, 030504 nursing, business.industry, Population, medicine.disease, Comorbidity, Pulmonary function testing, Original Article of GARD Section, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Relative risk, Internal medicine, Cohort, Medicine, 030212 general & internal medicine, 0305 other medical science, business, Prospective cohort study, education
Abstract: Background: Subjects with chronic obstructive pulmonary disease (COPD) present increased mortality and poor health-related quality of life (HRQoL) as compared with the general population. The objective of this study was to evaluate whether an improvement in QoL after 1 year of proper management is a predictor of survival in a cohort of patients followed up for 10 years. Methods: In this prospective study, 306 COPD patients were assessed for eligibility between January 2003 and September 2003. Thirty-five patients were excluded due to failure to meet inclusion criteria or declining to participate and 20 patients were also excluded subsequently because they could not complete the questionnaire. Two hundred and fifty one patients were assessed at the beginning. St. George Respiratory Questionnaire (SGRQ) and pulmonary function test (PFT) were performed at the initial visit and the end of the first year. Mortality information was obtained from hospital records and direct family interviews. Results: A comparison between respiratory diseases mortality according to baseline paramaters reveals that age and presence of cardiac comorbidity indicates a higher risk of death and associated with worse QoL. After a cox regression analysis, the relative risk of death of any cause related to baseline QoL score was 1.042 (95% CI: 1.028–1.057), and 1.030 (95% CI: 1.011–1.050) for respiratory cause mortality. However, the relative risk of death when there was a deterioration in QoL after one year of follow up was 1.175 (95% CI: 1.130–1.221) for all-cause mortality and 1.214 (95% CI: 1.151–1.280) for respiratory cause mortality. Conclusions: A QoL worsening in the initial year of follow up more strongly predicts 10-year mortality of any cause and for respiratory diseases than the baseline assessment alone predicts, among patients with COPD.
Published: 2019

38. Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases -Meeting Report (Part 1)

Author: Elaine Colgan, Mario Sánchez-Borges, Jim Phillips, Ignacio J. Ansotegui, Bolesław Samoliński, Olga Lourenço, Giorgio Walter Canonica, F. Portejoie, Isabella Annesi-Maesano, Gabrielle L. Onorato, Victoria Cardona, João O. Malva, Eugene Cash, Christine Rolland, Hilary Pinnock, Samantha Walker, Yoshitaka Okamoto, Ana Maria Carriazo, Lorenzo Cecchi, Nikos G. Papadopoulos, Jean Bousquet, L. T. T. Le, João Fonseca, Oliver Pfaar, Luis Caraballo, Elísio Costa, Maritta Perala, Pablo Quinones-Delgado, Torsten Zuberbier, Holger J. Schünemann, Tomohisa Iinuma, Enrica Menditto, Maddalena Illario, Nils E. Billo, Arunas Valiulis, Sinthia Bosnic-Anticevich, Josep M. Antó, Nick A. Guldemond, Maria Teresa Ventura, Claus Bachert, Wytske Fokkens, Lars Münter, Mohamed H. Shamji, Ioana Agache, Ulysse Rodts, Daniel Laune, Sanna Toppila-Salmi, Joaquim Mullol, Ioanna Tsiligianni, Motohiro Ebisawa, Isabelle Bosse, Samuel Benveniste, Arzu Yorgancioglu, Alkis Togias, M. Bewick, Nhân Pham-Thi, Stephen R. Durham, Moises A. Calderon, Marina Erhola, Violeta Kvedariene, Omar S. Usmani, Alvaro A. Cruz, Anna Bedbrook, Abigail Phillips, Desiree Larenas-Linneman, Guy Brusselle, Gert Marien, Dana Wallace, David Somekh, Sian Williams, Wienczyslawa Czarlewski, Ludger Klimek, Piotr Kuna, Jean-Luc Fauquert, Rianne van der Kleij, Derek K. Chu, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Service de Pneumologie Allergologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris], Transilvania University of Brasov, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospital Quiròn Bizkaia Erandio, Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), Ghent University Hospital, Centre de Recherche en Informatique (CRI), MINES ParisTech - École nationale supérieure des mines de Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], iQ4U consultants Ltd, University of Joensuu, The University of Sydney, Imperial College London, Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Institute for Immunological Research (University of Cartagena), Vall d'Hebron University Hospital [Barcelona], Servicio Andaluz de Salud, Nova Southeastern University (NSU), Azienda Sanitaria di Prato, McMaster University [Hamilton, Ontario], DEPARTMENT OF HEALTH ( Social Services and Public Safety), Universidade do Porto, Universidade Federal da Bahia (UFBA), UCB Pharma, Colombes, Sagamihara National Hospital, National Institute for Health and Welfare [Helsinki], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Faculdade de Medicina da Universidade do Porto (FMUP), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Chiba University Hospital, 'Federico II' University of Naples Medical School, Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Medical University of Łódź (MUL), Vilnius University [Vilnius], Hospital Medica Sur [Mexico City, Mexico], KYomed INNOV, Ho Chi Minh City University of Technology (HCMUT), Faculty of Health Sciences and CICS-UB (Health Sciences Research Centre), University of Coimbra [Portugal] (UC), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Department of Public Health [Copenhagen], Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), University of Manchester [Manchester], University of Athens Medical School [Athens], University of Oulu, Philipps University of Marburg, Cardiff University, University of Edinburgh, Regional Government for Equality, Medical University of Warsaw - Poland, Centro Medico-Docente La Trinidad, Department of Clinical Epidemiology and Biostatistics and Medicine, National Institute of Allergy and Infectious Diseases [Bethesda] (NIAID-NIH), National Institutes of Health [Bethesda] (NIH), University of Helsinki, University of Crete [Heraklion] (UOC), National Heart and Lung Institute [London] (NHLI), Imperial College London-Royal Brompton and Harefield NHS Foundation Trust, King's College Hospital (KCH), Leiden University Medical Center (LUMC), University of Bari Aldo Moro (UNIBA), Manisa Celal Bayar University, Humboldt-Universität zu Berlin, Association Asthme et Allergie, Health Services Management & Organisation (HSMO), University Hospital Montpellier, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U 1168, VIMA, Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, EUFOREA, Brussels, Belgium, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, Germany, Allergy Department, Pasteur Institute, Paris, France, Faculty of Medicine, Transylvania University, Brasov, Romania, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM, Sorbonne Universités, Medical School Saint Antoine, Paris, France, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiolog a y Salud Pública (CIBERESP), Barcelona, Spain, Upper Airways Research Laboratory, ENT Dept., Ghent University Hospital, Ghent, Belgium, National Center of Expertise in Cognitive Stimulation (CEN STIMCO), Broca Hospital, Paris, France, Mines ParisTech CRI - PSL Research University, Fontainebleau, France, iQ4U Consultants Ltd., London, United Kingdom, Joensuu, Finland, Woolcock Institute of Medical Research, University of Sydney, Woolcock Emphysema Centre, Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Dept. of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Imperial College London, National Heart and Lung Institute, London, United Kingdom, Personalized Medicine Clinic Asthma and Allergy, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy, Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Edificio Biblioteca Primer piso, Cartagena, Colombia, Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia, Allergy Section, Department of Internal Medicine, Hospital Vall d’Hebron and ARADyAL Research Network, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, College of Psychology, Nova Southeastern University, School-related Psychological Assessments and Clinical Interventions Clinic, Ft Lauderdale, FL, United States, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Health Research Methods, Evidence, and Impact, Division of Immunology and Allergy, Department of Medicine, McMaster University, Hamilton, ON, Canada, Department of Health, Social Services and Public Safety, Belfast, United Kingdom, UCIBIO, REQUIMTE, Faculty of Pharmacy, Competence Center on Active and Healthy Ageing of University of Porto (AgeUPNetWork), University of Porto, Porto, Portugal, ProAR-Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Executive Committee, Bahia, Brazil, Medical Consulting Czarlewski, Levallois, France, Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital, Sagamihara, Japan, National Institute for Health and Welfare, Helsinki, Finland, CHU Clermont-Ferrand, Unité d’Allergologie de l’Enfant, Pôle Pédiatrique, Hôpital Estaing, Clermont-Ferrand, France, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina, Universidade do Porto, Medida, Lda, Porto, Portugal, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, Dept. of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R and D and DISMET), Naples, Italy, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, KYomed INNOV, Montpellier, France, University of Medicine and Pharmacy, Hochiminh City, Viet Nam, Faculty of Health Sciences, CICS-UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra, Ageing@Coimbra EIP-AHA Reference Site, Coimbra, Portugal, CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy, Rhinology Unit and Smell Clinic, ENT Department, Hospital Cl nic, Clinical and Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Danish Committee for Health Education, Copenhagen East, Denmark, Division of Infection, Immunity and Respiratory Medicine, Royal Manchester Children’s Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children’s Hospital 'P and A Kyriakou', University of Athens, Athens, Greece, University of Oulu, Faculty of Medicine, Oulun Yliopisto, Finland, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Germany, Department of Health and Social Services, Welsh Government, Cardiff, United Kingdom, Centre For Empowering Patients and Communities, Dublin, Ireland, Asthma UK Centre for Applied Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, Agency for Social Services and Dependency, Regional Government for Equality, Social Policies and Conciliation of Andalucia, Seville, Spain, Association Asthme et Allergie, Paris, France, KanopyMed, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela, Immunomodulation and Tolerance Group, Imperial College London, London, United Kingdom, Allergy and Clinical Immunology, Imperial College London, London, United Kingdom, European Health Futures Forum (EHFF), Dromahair, Ireland, Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, United States, Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland, Health Planning Unit, Department of Social Medicine, Faculty of Medicine, University of Crete, Crete, Greece, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, National Heart and Lung Institute (NHLI), Imperial College London, Royal Brompton Hospital, Airways Disease Section, London, United Kingdom, Asthma UK, London, United Kingdom, Nova Southeastern University, Fort Lauderdale, FL, United States, Vilnius University, Faculty of Medicine, Institute of Clinical Medicine, Institute of Health Sciences, Vilnius, Lithuania, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Universitätsmedizin Berlin, Humboldt-Uniersität zu Berlin, Berlin, Germany, Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Berlin, Germany, uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, Institut Pasteur [Paris] (IP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hospital Quirónsalud Bizkaia [Bilbao], Mines Paris - PSL (École nationale supérieure des mines de Paris), Universidade do Porto = University of Porto, Sagamihara National Hospital [Kanagawa, Japan], University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Philipps Universität Marburg = Philipps University of Marburg, Centro Médico Docente La Trinidad, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Humboldt University Of Berlin, Salvy-Córdoba, Nathalie, Universiteit Leiden, Bousquet, J., Pham-Thi, N., Bedbrook, A., Agache, I., Annesi-Maesano, I., Ansotegui, I., Anto, J. M., Bachert, C., Benveniste, S., Bewick, M., Billo, N., Bosnic-Anticevich, S., Bosse, I., Brusselle, G., Calderon, M. A., Canonica, G. W., Caraballo, L., Cardona, V., Carriazo, A. M., Cash, E., Cecchi, L., Chu, D. K., Colgan, E., Costa, E., Cruz, A. A., Czarlewski, W., Durham, S., Ebisawa, M., Erhola, M., Fauquert, J. -L., Fokkens, W. J., Fonseca, J. A., Guldemond, N., Iinuma, T., Illario, M., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linneman, D., Laune, D., Le, L. T. T., Lourenco, O., Malva, J. O., Marien, G., Menditto, E., Mullol, J., Munter, L., Okamoto, Y., Onorato, G. L., Papadopoulos, N. G., Perala, M., Pfaar, O., Phillips, A., Phillips, J., Pinnock, H., Portejoie, F., Quinones-Delgado, P., Rolland, C., Rodts, U., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Shamji, M., Somekh, D., Togias, A., Toppila-Salmi, S., Tsiligianni, I., Usmani, O., Walker, S., Wallace, D., Valiulis, A., Van Der Kleij, R., Ventura, M. T., Williams, S., Yorgancioglu, A., and Zuberbier, T.
Subjects: Pulmonary and Respiratory Medicine, Allergy, medicine.medical_specialty, Allergic and chronic respiratory diseases, [SDV.IMM] Life Sciences [q-bio]/Immunology, Allergic rhinitis - Asthma - Multimorbidity, Health care system, Health literacy, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Health care, medicine, Patient participation, mHealth, Asthma, Rhinitis, [SDV.EE]Life Sciences [q-bio]/Ecology, environment, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Newsletter of GARD Section, business.industry, Environmental exposure, medicine.disease, 3. Good health, Integrated care, [SDV.EE] Life Sciences [q-bio]/Ecology, environment, 030228 respiratory system, 13. Climate action, Family medicine, [SDV.IMM]Life Sciences [q-bio]/Immunology, 030211 gastroenterology & hepatology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; In all societies, the burden and cost of allergic and chronic respiratory diseases are increasing rapidly. Most economies are struggling to deliver modern health care effectively. There is a need to support the transformation of the health care system for integrated care with organizational health literacy. MASK (Mobile Airways Sentinel NetworK) (1), a new development of the ARIA (Allergic Rhinitis and its Impact on Asthma) initiative, and POLLAR (Impact of Air POLLution on Asthma and Rhinitis, EIT Health) (2), in collaboration with professional and patient organizations in the field of allergy and airway diseases, are proposing real-life integrated care pathways (ICPs) (3)-centred around the patient with rhinitis and using mHealth monitoring of environmental exposure (4).An expert meeting took place at the Pasteur Institute in Paris, December 3, 2018. The aim was to discuss next-generation care pathways: (I) Patient participation, health literacy and self-care through technology-assisted “patient activation”; (II) Implementation of care pathways by pharmacists and (III) Next-generation guidelines assessing the recommendations of GRADE guidelines in rhinitis and asthma using real-world evidence (RWE) assessed by mobile technology.The EU (5) and global political agendas are of great importance in supporting health care transformation. MASK has been recognized by DG Santé as a Good Practice (6) in the field of digitally-enabled, integrated, person-centred care.The one-day meeting objectives were clear (Figure 1). The meeting was followed by a workshop. The present paper reports the background of the two-day meeting.
Published: 2019

39. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA

Author: Jere Reijula, De Yun Wang, Ralph Mösges, Tomohisa Iinuma, Jean Luc Fauquert, Nelson Rosario, Yehia El-Gamal, René Maximiliano Gómez, Tari Haahtela, Vincenzo Patella, Lorenzo Cecchi, Petr Panzner, Yoshitaka Okamoto, Oliver Pfaar, Luis Caraballo, Paulo Augusto Moreira Camargos, Filip Raciborski, Florin Mihaltan, Ken Ohta, Brian J. Lipworth, Kimi Okubo, Juan Carlos Ivancevich, Fulvio Braido, Ioana Agache, Frederico S. Regateiro, Neven Miculinic, Tuula Vasankari, R. Emuzyte, Arunas Valiulis, Yousser Mohammad, Torsten Zuberbier, Osman M. Yusuf, Ewa Jassem, Cezmi A. Akdis, Jean Bousquet, Alessandro Fiocchi, Jan Hagemann, Claus Bachert, Davor Plavec, K. S. Bennoor, Marek Jutel, Désirée Larenas-Linnemann, Stephen Montefort, Stefano Del Giacco, Przemyslaw Kardas, Erkka Valovirta, Mark S. Dykewicz, Antonio Valero, Wienczyslawa Czarlewski, Thomas B. Casale, Gabrielle L. Onorato, Omer Kalayci, Ludger Klimek, Joaquin Sastre, João Fonseca, Siân Williams, Karl Christian Bergmann, Marek Niedoszytko, Bilun Gemicioglu, Mario E. Zernotti, Musa Khaitov, H. Neffen, Robert M. Naclerio, Joaquim Mullol, Ana Pereira, Piotr Kuna, Michael Makris, Maria Teresa Ventura, Ioanna Tsiligianni, Dirceu Solé, Arzu Yorgancioglu, Charlotte Suppli-Ulrik, M. Gotua, Emmanuel P. Prokopakis, Dana Wallace, Jorge Maspero, Wytske Fokkens, Eckard Hamelmann, Antonino Romano, Dejan Dokic, Todor A. Popov, Violeta Kvedariene, Derek K. Chu, Anna Bedbrook, Dermot Ryan, Motohiro Ebisawa, Tomas Chivato, Giovanni Passalacqua, Menachem Rottem, Mário Morais-Almeida, Victoria Cardona, Bolesław Samoliński, Cristiana Stellato, Nikolaos G. Papadopoulos, Milan Sova, Jaime Correia-de-Sousa, Sietze Reitsma, Cemal Cingi, Francesca Puggioni, Robyn E O'Hehir, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, HUS Internal Medicine and Rehabilitation, Department of Public Health, Clinicum, Keuhkosairauksien yksikkö, Helsinki University Hospital Area, University of Helsinki, University Medical Center of the Johannes Gutenberg-University Mainz, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), University of Wrocław [Poland] (UWr), Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Transilvania University of Brasov, Humboldt University Of Berlin, Medical Consulting Czarlewski, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), MASK-air, Ghent University Hospital, Sun Yat-Sen University [Guangzhou] (SYSU), Karolinska Institutet [Stockholm], National Institute of Diseases of the Chest and Hospital (NIDCH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Ospedale Policlinico San Martino [Genoa], Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), University of Cartagena, Foundation for the Development of Medical and Biological Sciences (FUNDEMEB), Vall d'Hebron University Hospital [Barcelona], Allergy Unit [Malaga, Spain] (National Network ARADyAL), Hospital Regional Universitario de Málaga = Regional University Hospital of Malaga [Spain], University of South Florida [Tampa] (USF), Azienda Usl Toscana centro [Firenze], CEU-San Pablo University and HM-Hospitals School of Medicine, McMaster University [Hamilton, Ontario], Eskisehir Osmangazi University, Universidade do Minho = University of Minho [Braga], Life and Health Sciences Research Institute [Braga] (ICVS), University of Minho [Braga], The International Primary Care Respiratory Group (IPCRG), Università degli Studi di Cagliari = University of Cagliari (UniCa), Sts. Cyril and Methodius University, Saint Louis University School of Medicine [St Louis], Sagamihara National Hospital [Kanagawa, Japan], Ain Shams University (ASU), Vilnius University [Vilnius], Service de Pédiatrie Générale [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Bambino Gesù Children’s Hospital [Rome, Italy], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, CUF Porto Hospital, Cerrahpasa Faculty of Medicine, Istanbul University, ALAS Medical Institute, Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Universität Bielefeld = Bielefeld University, Chiba University Hospital, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Medical University of Gdańsk, Faculty of Medicine [Hacettepe University], Hacettepe University = Hacettepe Üniversitesi, Medical University of Łódź (MUL), Federal Medicobiological Agency [Moscow, Russian Federation], Hospital Medica Sur [Mexico City, Mexico], Ninewells Hospital and Medical School [Dundee], University General Hospital ' Attikon ' [Athens, Greece], Argentine Association of Allergy and Immunology, Marius Nasta Institute of Pneumology, Tishreen University, Université de Damas = Damascus University, University of Malta [Malta], Hospital CUF Descobertas, Clinical Research International Ltd [Hamburg, Germany] (CRI), Johns Hopkins University School of Medicine [Baltimore], Nemours/Alfred I. du Pont Hospital for Children, Monash University [Melbourne], Tokyo National Hospital, Nippon Medical School [Tokyo, Japon], Medicine Charles University and General Faculty Hospital in Prague, Royal Manchester Children's Hospital, University of Manchester [Manchester], Università degli studi di Genova = University of Genoa (UniGe), 'Santa Maria della Speranza' Hospital, Philipps Universität Marburg = Philipps University of Marburg, J.J. Strossmayer University of Osijek, Children’s Hospital Srebrnjak [Zagreb, Croatia], St. Ivan Rilski University Hospital, University of Crete [Heraklion] (UOC), IRCCS Humanitas [Rozzano, Italy], Medical University of Warsaw - Poland, Centro Hospitalar e Universitário [Coimbra], Amsterdam UMC - Amsterdam University Medical Center, Istituto di Ricovero e Cura a Carattere Scientifico [Troina, Italy] (IRCCS), Oasi Maria Santissima Srl [Troina, Italy], Clinica G.B. Morgagni (Fondazione Mediterranea), Pontifical Catholic University of Paraná (PUCPR), Pontifícia Universidade Católica do Paraná (PUCPR), Ha’Emek Medical Center [Afula, Israel], Pediatric Endocrine Institute [Afula, Israel], Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], University of Edinburgh, Federal University of Sao Paulo (Unifesp), University Hospital Olomouc [Czech Republic], University of Salerno (UNISA), Copenhagen University Hospital, Universitat de Barcelona (UB), European Academy of Paediatrics (EAP/UEMS-SP), University of Turku, Suomen Terveystalo Allergy Clinic, Finnish Lung Health Association, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Nova Southeastern University (NSU), Yong Loo Lin School of Medicine [Singapore], Department of Biology, Faculty of Sciences & Liberal Arts, Celal Bayar University, Manisa Celal Bayar University, The Allergy & Asthma Institute, Pakistan (IPCRG), Universidad Nacional de Villa María, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Allergiezentrum Wiesbaden, Salvy-Córdoba, Nathalie, Ear, Nose and Throat, and AII - Inflammatory diseases
Subjects: 0301 basic medicine, Allergy, MESH: Asthma, Common Cold, allergic rhinitis, common cold, cough, COVID-19, smell, Consensus, Humans, SARS-CoV-2, Asthma, Rhinitis, Allergic, Disease, Care, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Immunology and Allergy, MESH: COVID-19, Rhinitis, [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, Common cold, 3. Good health, MESH: Rhinitis, Allergic, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Original Article, medicine.symptom, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Immunology, Signs and symptoms, Asymptomatic, 03 medical and health sciences, Allergic, COVID‐19, Internal medicine, medicine, MESH: SARS-CoV-2, MESH: Consensus, MESH: Humans, business.industry, Rhinitis, Sinusitis, and Upper Airway Disease, CARE, medicine.disease, 030104 developmental biology, 030228 respiratory system, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, 3121 General medicine, internal medicine and other clinical medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ORIGINAL ARTICLES, Airway, business, MESH: Common Cold
Abstract: Background Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases. Methods A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis. Results Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p < .001). Conclusions This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire.
Published: 2021

40. Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

Author: Bousquet, Jean, Cristol, Jean-Paul, Czarlewski, Wienczyslawa, Anto, Josep M, Martineau, Adrian, Haahtela, Tari, Fonseca, Susana C, Iaccarino, Guido, Blain, Hubert, Fiocchi, Alessandro, Canonica, G Walter, Fonseca, Joao A, Vidal, Alain, Choi, Hak-Jong, Kim, Hyun Ju, Le Moing, Vincent, Reynes, Jacques, Sheikh, Aziz, Akdis, Cezmi A, Zuberbier, Torsten, Amir Hamzah Abdul Latiff, Baharudin, Abdullah, Werner, Aberer, Nancy, Abusada, Ian, Adcock, Alejandro, Afani, Ioana, Agache, Xenofon, Aggelidis, Jenifer, Agustin, Cezmi, A Akdis, Mübeccel, Akdis, Mona, Al-Ahmad, Abou Al-Zahab Bassam, Hussam, Alburdan, Oscar, Aldrey-Palacios, Emilio Alvarez Cuesta, Hiba Alwan Salman, Ashraf, Alzaabi, Salma, Amade, Gene, Ambrocio, Rosana, Angles, Isabella, Annesi-Maesano, Ignacio, J Ansotegui, Josep, M Anto, Paula Ara Bardajo, Stefania, Arasi, Margarete, Arrais, Hasan, Arshad, Maria-Cristina, Artesani, Estrella, Asayag, Francesca, Avolio, Khuzama, Azhari, Claus, Bachert, Diego, Bagnasco, Ilaria, Baiardini, Nissera, Bajrović, Petros, Bakakos, Sergio Bakeyala Mongono, Christine, Balotro-Torres, Sergio, Barba, Cristina, Barbara, Elsa, Barbosa, Bruno, Barreto, Joan, Bartra, Xavier, Basagana, Eric, D Bateman, Lkhagvaa, Battur, Anna, Bedbrook, Martín Bedolla Barajas, Bianca, Beghé, Antra, Bekere, Elizabeth, Bel, Ali Ben Kheder, Mikael, Benson, Elena-Camelia, Berghea, Karl-Christian, Bergmann, Roberto, Bernardini, David, Bernstein, Mike, Bewick, Slawomir, Bialek, Artur, Białoszewski, Thomas, Bieber, Nils, E Billo, Maria-Beatrice, Bilo, Carsten, Bindslev-Jensen, Leif, Bjermer, Hubert, Blain, Irina, Bobolea, Malgorzata Bochenska Marciniak, Christine, Bond, Attilio, Boner, Matteo, Bonini, Sergio, Bonini, Sinthia, Bosnic-Anticevich, Isabelle, Bosse, Sofia, Botskariova, Jacques, Bouchard, Louis-Philippe, Boulet, Rodolphe, Bourret, Philippe, Bousquet, Fulvio, Braido, Andrew, Briggs, Christopher, E Brightling, Jan, Brozek, Luisa, Brussino, Roland, Buhl, Roxana, Bumbacea, Rosalva, Buquicchio, María-Teresa Burguete Cabañas, Andrew, Bush, William, W Busse, Jeroen, Buters, Fernan, Caballero-Fonseca, Moïses, A Calderon, Mario, Calvo, Paulo, Camargos, Thierry, Camuzat, R Canevari, F, Antonio, Cano, G Walter Canonica, Arnaldo, Capriles-Hulett, Luis, Caraballo, Vicky, Cardona, Kai-Hakon, Carlsen, Jonas Carmona Pirez, Jorge, Caro, Warner, Carr, Pedro, Carreiro-Martins, Fredelita, Carreon-Asuncion, Ana-Maria, Carriazo, Carme Carrion, Y Ribas, Thomas, Casale, Mary-Ann, Castor, Elizabeth, Castro, G Caviglia, A, Lorenzo, Cecchi, Alfonso Cepeda Sarabia, Maciej, Chalubinski, Ramanathan, Chandrasekharan, Yoon-Seok, Chang, Victoria, Chato-Andeza, Lida, Chatzi, Christina, Chatzidaki, Niels, H Chavannes, Claudia Chaves Loureiro, Aurora-Alejandra Chavez Garcia, Marta, Chelninska, Yuzhi, Chen, Lei, Cheng, Sharon, Chinthrajah, Tomas, Chivato, Ekaterine, Chkhartishvili, George, Christoff, Henry, Chrystyn, Derek, K Chu, Antonio, Chua, Alexander, Chuchalin, Kian Fan Chung, Alberto, Cicerán, Cemal, Cingi, Giorgio, Ciprandi, Ieva, Cirule, Ana-Carla, Coelho, Enrico, Compalati, Jannis, Constantinidis, Jaime Correia de Sousa, Elisio Manuel Costa, David, Costa, María Del Carmen Costa Domínguez, André, Coste, Cottini, M, Linda, Cox, Carlos, Crisci, Maria Angiola Crivellaro, Alvaro, A Cruz, John, Cullen, Adnan, Custovic, Biljana, Cvetkovski, Wienczyslawa, Czarlewski, Gennaro, D'Amato, Jane da Silva, Ronald, Dahl, Sven-Erik, Dahlen, Vasilis, Daniilidis, Louei Darjazini Nahhas, Ulf, Darsow, Janet, Davies, Frédéric de Blay, Giulia De Feo, Eloisa De Guia, José-Ricardo De la Torre Navarrete, Chato De Los Santos, Esteban De Manuel Keenoy, Govert De Vries, Diana, Deleanu, Pascal, Demoly, Judah, Denburg, Philippe, Devillier, Alain, Didier, Sanja Dimic Janjic, Maria, Dimou, Anh Tuan Dinh-Xuan, Ratko, Djukanovic, Maria Do Ceu Texeira, Dejan, Dokic, Margarita Gabriela Domínguez Silva, Habib, Douagui, Nikolaos, Douladiris, Maria, Doulaptsi, Gérard, Dray, Ruta, Dubakiene, Eve, Dupas, Stephen, Durham, Marzia, Duse, Mark, Dykewicz, Didier, Ebo, Natalija, Edelbaher, Thomas, Eiwegger, Patrik, Eklund, Yehia, El-Gamal, Zeinab, A El-Sayed, Shereen, S El-Sayed, Magda, El-Seify, Regina, Emuzyte, Lourdes, Enecilla, Marina, Erhola, Heidilita, Espinoza, Jesús Guillermo Espinoza Contreras, John, Farrell, Lenora, Fernandez, Paola Fimbres Jimenez, Antje Fink Wagner, Alessandro, Fiocchi, Wytske, J Fokkens, Lenia, Folletti, Joao, A Fonseca, Jean-François, Fontaine, Francesco, Forastiere, Jose Miguel Fuentes Pèrez, Emily, Gaerlan-Resureccion, Mina, Gaga, José Luis Gálvez Romero, Amiran, Gamkrelidze, Alexis, Garcia, Cecilia Yvonne García Cobas, María de la Luz Hortensia García Cruz, Valeria Garcia Ortiz, Jacques, Gayraud, Matteo, Gelardi, Bilun, Gemicioglu, Dimitra, Gennimata, Sonya, Genova, José, Gereda, Roy Gerth van Wijk, Antonio, Giuliano, René-Maximiliano, Gomez, Miguel-Ange Gonzalez Ballester, Sandra González Diaz, Maia, Gotua, Christos, Grigoreas, Ineta, Grisle, Marta, Guidacci, Nick, Guldemond, Zdenek, Gutter, Antonieta, Guzmán, Tari, Haahtela, Ramsa, Halloum, David, Halpin, Eckard, Hamelmann, Suleiman, Hammadi, Richard, Harvey, Enrico, Heffler, Joachim, Heinrich, Adnan, Hejjaoui, Birthe, Hellquist-Dahl, Luiana Hernández Velázquez, Mark, Hew, Elham, Hossny, Peter, Howarth, Martin, Hrubiško, Yunuen Rocío Huerta Villalobos, Marc, Humbert, Salina, Husain, Michael, Hyland, Guido, Iaccarino, Moustafa, Ibrahim, Nataliya, Ilina, Maddalena, Illario, Cristoforo, Incorvaia, Antonio, Infantino, Carla, Irani, Zhanat, Ispayeva, Juan Carlos Ivancevich, Edgardo Ej Jares, Deborah, Jarvis, Ewa, Jassem, Klemen, Jenko, Rubén Darío Jiméneracruz Uscanga, Sebastian, L Johnston, Guy, Joos, Maja, Jošt, Kaja, Julge, Ki-Suck, Jung, Jocelyne, Just, Marek, Jutel, Igor, Kaidashev, Omer, Kalayci, Fuat, Kalyoncu, Jeni, Kapsali, Przemyslaw, Kardas, Jussi, Karjalainen, Carmela, A Kasala, Michael, Katotomichelakis, Loreta, Kavaliukaite, Kazi, S Bennoor, Thomas, Keil, Paul, Keith, Musa, Khaitov, Nikolai, Khaltaev, You-Young, Kim, Bruce, Kirenga, Jorg, Kleine-Tebbe, Ludger, Klimek, Fanny, W Ko, Bernard Koffi N'Goran, Evangelia, Kompoti, Peter, Kopač, Gerard, Koppelman, Anja Koren Jeverica, Seppo, Koskinen, Mitja, Košnik, Tomasz, Kostka, Kosta, V Kostov, Marek, L Kowalski, Tanya, Kralimarkova, Karmen Kramer Vrščaj, Helga, Kraxner, Samo, Kreft, Vicky, Kritikos, Dmitry, Kudlay, Mikael, Kuitunen, Inger, Kull, Piotr, Kuna, Maciej, Kupczyk, Violeta, Kvedariene, Marialena, Kyriakakou, Nika, Lalek, Massimo, Landi, Stephen, Lane, Désiree, E Larenas-Linnemann, Susanne, Lau, Daniel, Laune, Jorge, Lavrut, Lan, Le, Martina, Lenzenhuber, Gualtiero, Leo, Marcus, Lessa, Michael, Levin, Jing, Li, Philip, Lieberman, Giuseppe, Liotta, Brian, Lipworth, Xuandao, Liu, Rommel, Lobo, Karin, C Lodrup Carlsen, Carlo, Lombardi, Renaud, Louis, Stelios, Loukidis, Olga, Lourenço, Jorge, A Luna Pech, Bojan, Madjar, Enrico, Maggi, Antoine, Magnan, Bassam, Mahboub, Alpana, Mair, Anke-Hilse Maitland van der Zee, Mika, Makela, Michael, Makris, Hans-Jorgen, Malling, Mariana, Mandajieva, Patrick, Manning, Manolis, Manousakis, Pavlos, Maragoudakis, Gianluigi, Marseglia, Gailen, Marshall, Mohammad Reza Masjedi, Jorge, F Máspero, Juan José Matta Campos, Marcus, Maurer, Sandra, Mavale-Manuel, Cem, Meço, Erik, Melén, Giovanni, Melioli, Elisabete, Melo-Gomes, Eli, O Meltzer, Enrica, Menditto, Andrew, Menzies-Gow, Hans, Merk, Jean-Pierre, Michel, Yann, Micheli, Neven, Miculinic, Luís, Midão, Florin, Mihaltan, Nikolaos, Mikos, Manlio, Milanese, Branislava, Milenkovic, Dimitrios, Mitsias, Bassem, Moalla, Giuliana, Moda, María Dolores Mogica Martínez, Yousser, Mohammad, Frances-Montserrat, Moharra, Mostafa, Moin, Mathieu, Molimard, Isabelle, Momas, Monique, Mommers, Alessandro, Monaco, Stephen, Montefort, Lucia-Elvira, Montenegro, Riccardo, Monti, Dory, Mora, Mario, Morais-Almeida, Ralph, Mösges, Badr Eldin Mostafa, Joaquim, Mullol, Lars, Münter, Antonella, Muraro, Ruth, Murray, Antonio, Musarra, Tihomir, Mustakov, Robert, Naclerio, Kari, C Nadeau, Rachel, Nadif, Alla, Nakonechna, Leyla, Namazova-Baranova, Gretchen, Navarro-Locsin, Hugo, Neffen, Kristof, Nekam, Angelos, Neou, Eustachio, Nettis, Daniel, Neuberger, Laurent, Nicod, Stefania, Nicola, Verena, Niederberger-Leppin, Marek, Niedoszytko, Antonio, Nieto, Ettore, Novellino, Elizabete, Nunes, Dieudonné, Nyembue, Robyn, E O'Hehir, Cvetanka, Odjakova, Ken, Ohta, Yoshitaka, Okamoto, Kimi, Okubo, Brian, Oliver, Gabrielle, L Onorato, Maria Pia Orru, Solange, Ouédraogo, Kampadilemba, Ouoba, Francisco-Javier, Padilla, Pier Luigi Paggiaro, Aris, Pagkalos, Pajno, Giovanni Battista, Gianni, Pala, P Palaniappan, S, Isabella, Pali-Schöll, Susanna, Palkonen, Stephen, Palmer, Carmen Panaitescu Bunu, Petr, Panzner, Nikos, G Papadopoulos, Vasilis, Papanikolaou, Alberto, Papi, Bojidar, Paralchev, Giannis, Paraskevopoulos, Hae-Sim, Park, Giovanni, Passalacqua, Vincenzo, Patella, Ian, Pavord, Ruby, Pawankar, Soren, Pedersen, Susete, Peleve, Simona, Pellegino, Ana, Pereira, Mariana, Pereira, Tamara, Pérez, Andrea, Perna, Diego, Peroni, Oliver, Pfaar, Nhân, Pham-Thi, Bernard, Pigearias, Isabelle, Pin, Konstantina, Piskou, Constantinos, Pitsios, Davor, Plavec, Dagmar, Poethig, Wolfgang, Pohl, Antonija Poplas Susic, Todor, A Popov, Fabienne, Portejoie, Paul, Potter, Lars, Poulsen, Alexandra, Prados-Torres, Fotis, Prarros, David, Price, Emmanuel, Prokopakis, Francesca, Puggioni, Elisa, Puig-Domenech, Robert, Puy, Klaus, Rabe, Silvia, Rabotti, Filip, Raciborski, Josephine, Ramos, Cristina, Recalcati, Marysia, T Recto, Shereen, M Reda, Frederico, S Regateiro, Norbert, Reider, Sietze, Reitsma, Susana, Repka-Ramirez, Erminia, Ridolo, Janet, Rimmer, Daniela Rivero Yeverino, José Angelo Rizzo, Carlos, Robalo-Cordeiro, Graham, Roberts, Karen, Robles, Nicolas, Roche, Mónica Rodríguez González, Eréndira Rodríguez Zagal, Giovanni, Rolla, Christine, Rolland, Regina, Roller-Wirnsberger, Miguel Roman Rodriguez, Antonino, Romano, Jan, Romantowski, Philippe, Rombaux, Joel, Romualdez, Jose, Rosado-Pinto, Nelson, Rosario, Lanny, Rosenwasser, Oliviero, Rossi, Menachem, Rottem, Philip, W Rouadi, Nikoleta, Rovina, Irma Rozman Sinur, Mauricio, Ruiz, Lucy Tania Ruiz Segura, Dermot, Ryan, Hironori, Sagara, Daiki, Sakai, Daiju, Sakurai, Wafaa, Saleh, Johanna, Salimaki, Konstantinos, Samitas, Boleslaw, Samolinski, María Guadalupe Sánchez Coronel, Mario, Sanchez-Borges, Jaime, Sanchez-Lopez, Melissa, Sansonna, Codrut, Sarafoleanu, Faradiba Sarquis Serpa, Joaquin, Sastre, Eleonora, Savi, Agne, Savonyte, Bisher, Sawaf, Glenis, K Scadding, Sophie, Scheire, Peter, Schmid-Grendelmeier, Juan Francisco Schuhl, Holger, Schunemann, Maria, Schvalbová, Jorgen, Schwarze, Nicola, Scichilone, Gianenrico, Senna, Cecilia, Sepúlveda, Elie, Serrano, Sara, Shamai, Aziz, Sheikh, Mike, Shields, Vasil, Shishkov, Nikos, Siafakas, Alexander, Simeonov, Estelle Fer Simons, Juan Carlos Sisul, Brigita, Sitkauskiene, Ingelbjorg, Skrindo, Tanja Soklič Košak, Dirceu, Solé, Martin, Sondermann, Talant, Sooronbaev, Manuel, Soto-Martinez, Manuel, Soto-Quiros, Barnaro Sousa Pinto, Milan, Sova, Michael, Soyka, Krzysztof, Specjalski, Annette, Sperl, Otto, Spranger, Sofia, Stamataki, Lina, Stefanaki, Cristiana, Stellato, Rafael, Stelmach, Timo, Strandberg, Petra, Stute, Abirami, Subramaniam, Charlotte Suppli Ulrik, Michael, Sutherland, Silvia, Sylvestre, Aikaterini, Syrigou, Luis Taborda Barata, Nadejda, Takovska, Rachel, Tan, Frances, Tan, Vincent, Tan, Ing Ping Tang, Masami, Taniguchi, Line, Tannert, Pongsakorn, Tantilipikorn, Jessica, Tattersall, Filippo, Tesi, Uta, Thieme, Carel, Thijs, Mike, Thomas, Teresa, To, Ana Maria Todo-Bom, Alkis, Togias, Peter-Valentin, Tomazic, Vesna, Tomic-Spiric, Sanna, Toppila-Salmi, Maria-José Torres Jaen, Elina, Toskala, Massimo, Triggiani, Nadja, Triller, Katja, Triller, Ioanna, Tsiligianni, Uberti, M, Ruxandra, Ulmeanu, Jure, Urbancic, Marilyn Urrutia Pereira, Martina, Vachova, Felipe, Valdés, Rudolf, Valenta, Marylin Valentin Rostan, Antonio, Valero, Arunas, Valiulis, Mina, Vallianatou, Erkka, Valovirta, Michiel Van Eerd, Eric Van Ganse, Marianne van Hage, Olivier, Vandenplas, Tuula, Vasankari, Dafina, Vassileva, Cesar Velasco Munoz, Maria Teresa Ventura, Cécilia, Vera-Munoz, Frédéric, Viart, Dilyana, Vicheva, Pakit, Vichyanond, Petra, Vidgren, Giovanni, Viegi, Claus, Vogelmeier, Leena Von Hertzen, Theodoros, Vontetsianos, Dimitris, Vourdas, Vu Tran Thien Quan, Martin, Wagenmann, Samantha, Walker, Dana, Wallace, Yun De Wang, Susan, Waserman, Katrin, Wehner, Magnus, Wickman, Sian, Williams, Dennis, Williams, Nicola, Wilson, Gary, Wong, Kent, Woo, Lucyna, Wozniak, John, Wright, Piotr, Wroczynski, Paraskevi, Xepapadaki, Plamen, Yakovliev, Masao, Yamaguchi, Kwok, Yan, Yoke Yeow Yap, Mais, Yassin, Barbara, Yawn, Panayiotis, Yiallouros, Arzu, Yorgancioglu, Shigemi, Yoshihara, Ian, Young, Osman, B Yusuf, Asghar, Zaidi, Fares, Zaitoun, Petra, Zalud, Heather, Zar, T Zedda, M, Mario, E Zernotti, Luo, Zhang, Nanshan, Zhong, Mihaela, Zidarn, Torsten, Zuberbier, Celia, Zubrinich, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Humboldt University Of Berlin, Berlin Institute of Health (BIH), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), IMIM-Hospital del Mar, Generalitat de Catalunya, Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Barts & The London School of Medicine and Dentistry, Queen Mary University of London (QMUL), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Helsinki University Central Hospital [Finland] (HUCH), Departamento de Geociencias, Ambiente e Ordenamento do Territorio (DGAOT), Universidade do Porto = University of Porto, University of Naples Federico II = Università degli studi di Napoli Federico II, Euromov (EuroMov), Université de Montpellier (UM), IRCCS Ospedale Pediatrico Bambino Gesù [Roma], Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed), Center of Research in Health Technologies and Information Systems (CINTESIS), AgroParisTech, World Institute of Kimchi [Gwangju], Département Maladies Infectieuses et Tropicales, Hôpital Universitaire, Montpellier, France, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Edinburgh, Universität Zürich [Zürich] = University of Zurich (UZH), Humboldt-Universität zu Berlin, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of Helsinki, Universidade do Porto, University of Naples Federico II, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), MORNET, Dominique, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet J., Cristol J.-P., Czarlewski W., Anto J.M., Martineau A., Haahtela T., Fonseca S.C., Iaccarino G., Blain H., Fiocchi A., Canonica G.W., Fonseca J.A., Vidal A., Choi H.-J., Kim H.J., Le Moing V., Reynes J., Sheikh A., Akdis C.A., Zuberbier T., Abdul Latiff A.H., Abdullah B., Aberer W., Abusada N., Adcock I., Afani A., Agache I., Aggelidis X., Agustin J., Akdis M., Al-Ahmad M., Al-Zahab Bassam A., Alburdan H., Aldrey-Palacios O., Alvarez Cuesta E., Alwan Salman H., Alzaabi A., Amade S., Ambrocio G., Angles R., Annesi-Maesano I., Ansotegui I.J., Ara Bardajo P., Arasi S., Arrais M., Arshad H., Artesani M.-C., Asayag E., Avolio F., Azhari K., Bachert C., Bagnasco D., Baiardini I., Bajrovic N., Bakakos P., Bakeyala Mongono S., Balotro-Torres C., Barba S., Barbara C., Barbosa E., Barreto B., Bartra J., Basagana X., Bateman E.D., Battur L., Bedbrook A., Bedolla Barajas M., Beghe B., Bekere A., Bel E., Ben Kheder A., Benson M., Berghea E.-C., Bergmann K.-C., Bernardini R., Bernstein D., Bewick M., Bialek S., Bialoszewski A., Bieber T., Billo N.E., Bilo M.-B., Bindslev-Jensen C., Bjermer L., Bobolea I., Bochenska Marciniak M., Bond C., Boner A., Bonini M., Bonini S., Bosnic-Anticevich S., Bosse I., Botskariova S., Bouchard J., Boulet L.-P., Bourret R., Bousquet P., Braido F., Briggs A., Brightling C.E., Brozek J., Brussino L., Buhl R., Bumbacea R., Buquicchio R., Burguete Cabanas M.-T., Bush A., Busse W.W., Buters J., Caballero-Fonseca F., Calderon M.A., Calvo M., Camargos P., Camuzat T., Canevari F., Cano A., Canonican G.W., Capriles-Hulett A., Caraballo L., Cardona V., Carlsen K.-H., Carmona Pirez J., Caro J., Carr W., Carreiro-Martins P., Carreon-Asuncion F., Carriazo A.-M., CarrionyRibas C., Casale T., Castor M.-A., Castro E., Caviglia A.G., Cecchi L., Cepeda Sarabia A., Chalubinski M., Chandrasekharan R., Chang Y.-S., Chato-Andeza V., Chatzi L., Chatzidaki C., Chavannes N.H., Chaves Loureiro C., Chavez Garcia A.-A., Chelninska M., Chen Y., Cheng L., Chinthrajah S., Chivato T., Chkhartishvili E., Christoff G., Chrystyn H., Chu D.K., Chua A., Chuchalin A., Chung K.F., Ciceran A., Cingi C., Ciprandi G., Cirule I., Coelho A.-C., Compalati E., Constantinidis J., Correia de Sousa J., Costa E.M., Costa D., del Carmen Costa Dominguez M., Coste A., Cottini M., Cox L., Crisci C., Crivellaro M.A., Cruz A.A., Cullen J., Custovic A., Cvetkovski B., D'Amato G., da Silva J., Dahl R., Dahlen S.-E., Daniilidis V., Darjazini Nahhas L., Darsow U., Davies J., de Blay F., De Feo G., De Guia E., De la Torre Navarrete J.-R., De los Santos C., De Manuel Keenoy E., De Vries G., Deleanu D., Demoly P., Denburg J., Devillier P., Didier A., Dimic Janjic S., Dimou M., Dinh-Xuan A.T., Djukanovic R., Do Ceu Texeira M., Dokic D., Dominguez Silva M.G., Douagui H., Douladiris N., Doulaptsi M., Dray G., Dubakiene R., Dupas E., Durham S., Duse M., Dykewicz M., Ebo D., Edelbaher N., Eiwegger T., Eklund P., El-Gamal Y., El-Sayed Z.A., El-Sayed S.S., El-Seify M., Emuzyte R., Enecilla L., Erhola M., Espinoza H., Espinoza Contreras J.G., Farrell J., Fernandez L., Fimbres Jimenez P., Fink Wagner A., Fokkens W.J., Folletti L., Fontaine J.-F., Forastiere F., Fuentes Perez J.M., Gaerlan-Resureccion E., Gaga M., Galvez Romero J.L., Gamkrelidze A., Garcia A., Garcia Cobas C.Y., de la Luz Hortensia Garcia Cruz M., Ortiz V.G., Gayraud J., Gelardi M., Gemicioglu B., Gennimata D., Genova S., Gereda J., Gerth van Wijk R., Giuliano A., Gomez R.-M., Gonzalez Ballester M.-A., Gonzalez Diaz S., Gotua M., Grigoreas C., Grisle I., Guidacci M., Guldemond N., Gutter Z., Guzman A., Halloum R., Halpin D., Hamelmann E., Hammadi S., Harvey R., Heffler E., Heinrich J., Hejjaoui A., Hellquist-Dahl B., Hernandez Velazquez L., Hew M., Hossny E., Howarth P., Hrubisko M., Huerta Villalobos Y.R., Humbert M., Husain S., Hyland M., Ibrahim M., Ilina N., Illario M., Incorvaia C., Infantino A., Irani C., Ispayeva Z., Ivancevich J.C., Jares E.E., Jarvis D., Jassem E., Jenko K., Jimeneracruz Uscanga R.D., Johnston S.L., Joos G., Jost M., Julge K., Jung K.-S., Just J., Jutel M., Kaidashev I., Kalayci O., Kalyoncu F., Kapsali J., Kardas P., Karjalainen J., Kasala C.A., Katotomichelakis M., Kavaliukaite L., Bennoor K.S., Keil T., Keith P., Khaitov M., Khaltaev N., Kim Y.-Y., Kirenga B., Kleine-Tebbe J., Klimek L., Ko F.W., Koffi N'Goran B., Kompoti E., Kopac P., Koppelman G., Koren Jeverica A., Koskinen S., Kosnik M., Kostka T., Kostov K.V., Kowalski M.L., Kralimarkova T., Kramer Vrscaj K., Kraxner H., Kreft S., Kritikos V., Kudlay D., Kuitunen M., Kull I., Kuna P., Kupczyk M., Kvedariene V., Kyriakakou M., Lalek N., Landi M., Lane S., Larenas-Linnemann D.E., Lau S., Laune D., Lavrut J., Le L., Lenzenhuber M., Leo G., Lessa M., Levin M., Li J., Lieberman P., Liotta G., Lipworth B., Liu X., Lobo R., Lodrup Carlsen K.C., Lombardi C., Louis R., Loukidis S., Lourenco O., Luna Pech J.A., Madjar B., Maggi E., Magnan A., Mahboub B., Mair A., Maitland van der Zee A.-H., Makela M., Makris M., Malling H.-J., Mandajieva M., Manning P., Manousakis M., Maragoudakis P., Marseglia G., Marshall G., Masjedi M.R., Maspero J.F., Matta Campos J.J., Maurer M., Mavale-Manuel S., Meco C., Melen E., Melioli G., Melo-Gomes E., Meltzer E.O., Menditto E., Menzies-Gow A., Merk H., Michel J.-P., Micheli Y., Miculinic N., Midao L., Mihaltan F., Mikos N., Milanese M., Milenkovic B., Mitsias D., Moalla B., Moda G., Mogica Martinez M.D., Mohammad Y., Moharra F.-M., Moin M., Molimard M., Momas I., Mommers M., Monaco A., Montefort S., Montenegro L.-E., Monti R., Mora D., Morais-Almeida M., Mosges R., Mostafa B.E., Mullol J., Munter L., Muraro A., Murray R., Musarra A., Mustakov T., Naclerio R., Nadeau K.C., Nadif R., Nakonechna A., Namazova-Baranova L., Navarro-Locsin G., Neffen H., Nekam K., Neou A., Nettis E., Neuberger D., Nicod L., Nicola S., Niederberger-Leppin V., Niedoszytko M., Nieto A., Novellino E., Nunes E., Nyembue D., O'Hehir R.E., Odjakova C., Ohta K., Okamoto Y., Okubo K., Oliver B., Onorato G.L., Orru M.P., Ouedraogo S., Ouoba K., Padilla F.-J., Paggiaro P.L., Pagkalos A., Pajno G., Pala G., Palaniappan S., Pali-Scholl I., Palkonen S., Palmer S., Panaitescu Bunu C., Panzner P., Papadopoulos N.G., Papanikolaou V., Papi A., Paralchev B., Paraskevopoulos G., Park H.-S., Passalacqua G., Patella V., Pavord I., Pawankar R., Pedersen S., Peleve S., Pellegino S., Pereira A., Pereira M., Perez T., Perna A., Peroni D., Pfaar O., Pham-Thi N., Pigearias B., Pin I., Piskou K., Pitsios C., Plavec D., Poethig D., Pohl W., Poplas Susic A., Popov T.A., Portejoie F., Potter P., Poulsen L., Prados-Torres A., Prarros F., Price D., Prokopakis E., Puggioni F., Puig-Domenech E., Puy R., Rabe K., Rabotti S., Raciborski F., Ramos J., Recalcati C., Recto M.T., Reda S.M., Regateiro F.S., Reider N., Reitsma S., Repka-Ramirez S., Ridolo E., Rimmer J., Rivero Yeverino D., Rizzo J.A., Robalo-Cordeiro C., Roberts G., Robles K., Roche N., Rodriguez Gonzalez M., Rodriguez Zagal E., Rolla G., Rolland C., Roller-Wirnsberger R., Roman Rodriguez M., Romano A., Romantowski J., Rombaux P., Romualdez J., Rosado-Pinto J., Rosario N., Rosenwasser L., Rossi O., Rottem M., Rouadi P.W., Rovina N., Rozman Sinur I., Ruiz M., Ruiz Segura L.T., Ryan D., Sagara H., Sakai D., Sakurai D., Saleh W., Salimaki J., Samitas K., Samolinski B., Sanchez Coronel M.G., Sanchez-Borges M., Sanchez-Lopez J., Sansonna M., Sarafoleanu C., Sarquis Serpa F., Sastre J., Savi E., Savonyte A., Sawaf B., Scadding G.K., Scheire S., Schmid-Grendelmeier P., Schuhl J.F., Schunemann H., Schvalbova M., Schwarze J., Scichilone N., Senna G., Sepulveda C., Serrano E., Shamai S., Shields M., Shishkov V., Siafakas N., Simeonov A., Simons E.F., Sisul J.C., Sitkauskiene B., Skrindo I., Soklic Kosak T., Sole D., Sondermann M., Sooronbaev T., Soto-Martinez M., Soto-Quiros M., Pinto B.S., Sova M., Soyka M., Specjalski K., Sperl A., Spranger O., Stamataki S., Stefanaki L., Stellato C., Stelmach R., Strandberg T., Stute P., Subramaniam A., Suppli Ulrik C., Sutherland M., Sylvestre S., Syrigou A., Taborda Barata L., Takovska N., Tan R., Tan F., Tan V., Tang I.P., Taniguchi M., Tannert L., Tantilipikorn P., Tattersall J., Tesi F., Thieme U., Thijs C., Thomas M., To T., Todo-Bom A.M., Togias A., Tomazic P.-V., Tomic-Spiric V., Toppila-Salmi S., Torres Jaen M.-J., Toskala E., Triggiani M., Triller N., Triller K., Tsiligianni I., Uberti M., Ulmeanu R., Urbancic J., Urrutia Pereira M., Vachova M., Valdes F., Valenta R., Valentin Rostan M., Valero A., Valiulis A., Vallianatou M., Valovirta E., Van Eerd M., Van Ganse E., van Hage M., Vandenplas O., Vasankari T., Vassileva D., Velasco Munoz C., Ventura M.T., Vera-Munoz C., Viart F., Vicheva D., Vichyanond P., Vidgren P., Viegi G., Vogelmeier C., Von Hertzen L., Vontetsianos T., Vourdas D., Tran Thien Quan V., Wagenmann M., Walker S., Wallace D., De Wang Y., Waserman S., Wehner K., Wickman M., Williams S., Williams D., Wilson N., Wong G., Woo K., Wozniak L., Wright J., Wroczynski P., Xepapadaki P., Yakovliev P., Yamaguchi M., Yan K., Yap Y.Y., Yassin M., Yawn B., Yiallouros P., Yorgancioglu A., Yoshihara S., Young I., Yusuf O.B., Zaidi A., Zaitoun F., Zalud P., Zar H., Zedda M.T., Zernotti M.E., Zhang L., Zhong N., and Zidarn M.
Subjects: MAPK/ERK pathway, ARIA group, Allergy, [SDV]Life Sciences [q-bio], NF-KAPPA-B, debelost, Review, Pharmacology, Resveratrol, PROTECTS, chemistry.chemical_compound, 0302 clinical medicine, RESPIRATORY SYNDROME CORONAVIRUS, ENDOPLASMIC-RETICULUM STRESS, Medicine and Health Sciences, Immunology and Allergy, Medicine, OXIDATIVE STRESS, COVID-19, Foods, Insulin resistance, Nrf2, Nutrients, Obesity, TRPA1, 2. Zero hunger, 0303 health sciences, RESPIRATORY, INSULIN-RESISTANCE, Muscle cell proliferation, SULFORAPHANE, 3. Good health, [SDV] Life Sciences [q-bio], 030220 oncology & carcinogenesis, SIGNALING PATHWAY, Signal transduction, Life Sciences & Biomedicine, Pulmonary and Respiratory Medicine, NRF2 ACTIVATORS, MUSCLE-CELL PROLIFERATION, Immunology, 610 Medicine & health, Lung injury, Settore MED/10 - Malattie Dell'Apparato Respiratorio, ACUTE LUNG INJURY, 03 medical and health sciences, COVID-19, Foods, Insulin resistance, Nrf2, Nutrients, Obesity, TRPA1, udc:616.9, odpornost proti inzulinu, SULFORAPHANE PROTECTS, Transcription factor, PI3K/AKT/mTOR pathway, 030304 developmental biology, Science & Technology, business.industry, SARS-CoV-2, food, medicine.disease, chemistry, hranila, SYNDROME CORONAVIRUS, business, hrana, GREEN TEA
Abstract: There are large between- and within-country variations in COVID-19 death rates. Some very low death rate settings such as Eastern Asia, Central Europe, the Balkans and Africa have a common feature of eating large quantities of fermented foods whose intake is associated with the activation of the Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) anti-oxidant transcription factor. There are many Nrf2-interacting nutrients (berberine, curcumin, epigallocatechin gallate, genistein, quercetin, resveratrol, sulforaphane) that all act similarly to reduce insulin resistance, endothelial damage, lung injury and cytokine storm. They also act on the same mechanisms (mTOR: Mammalian target of rapamycin, PPARγ:Peroxisome proliferator-activated receptor, NFκB: Nuclear factor kappa B, ERK: Extracellular signal-regulated kinases and eIF2α:Elongation initiation factor 2α). They may as a result be important in mitigating the severity of COVID-19, acting through the endoplasmic reticulum stress or ACE-Angiotensin-II-AT1R axis (AT1R) pathway. Many Nrf2-interacting nutrients are also interacting with TRPA1 and/or TRPV1. Interestingly, geographical areas with very low COVID-19 mortality are those with the lowest prevalence of obesity (Sub-Saharan Africa and Asia). It is tempting to propose that Nrf2-interacting foods and nutrients can re-balance insulin resistance and have a significant effect on COVID-19 severity. It is therefore possible that the intake of these foods may restore an optimal natural balance for the Nrf2 pathway and may be of interest in the mitigation of COVID-19 severity.
Published: 2020

41. Airway Diseases

Author: Cemal Cingi, Arzu Yorgancıoğlu, Nuray Bayar Muluk, Alvaro A. Cruz, Cemal Cingi, Arzu Yorgancıoğlu, Nuray Bayar Muluk, and Alvaro A. Cruz
Subjects: Otorhinolaryngology, Respiratory organs—Diseases, Pediatrics
Abstract: This book provides a comprehensive and up-to-date overview of all the upper and lower airways disorders and broadens their understanding by combining ENT and pulmonology disciplines. The volume opens with a general overview on the airways, before describing symptoms, infections and allergies. In addition to the upper airway tumors, specific lower, and upper airway disorders, other topics addressed by the book are pediatric lower airway disorders, sleep related breathing disorders, trauma, reflux, and interventional pulmonology. The closing part discusses the airway protection and includes a chapter on gender and pulmonary diseases. Written by experts in the fields, the book is a valuable resource for both specialists and trainees in ENT, pulmonology, and pediatrics.
Published: 2023

42. Does Rhinitis Pharmacotherapy Improve Control of Comorbid Asthma?

Author: Arzu Yorgancioglu, Funda Çelik Şenel, and Alvaro A. Cruz
Subjects: medicine.medical_specialty, Sneeze, business.industry, Provocation test, respiratory system, medicine.disease, Dermatology, respiratory tract diseases, Pharmacotherapy, medicine.anatomical_structure, Wheeze, medicine, Sputum, medicine.symptom, business, Airway, Nose, Asthma
Abstract: Asthma is a disorder usually characterised by chronic inflammation of the airway mucosa of the bronchi and also the more distal airways, featuring a varying (and often remediable) degree of airflow limitation, hyperreactivity of the bronchi and periodic flare-ups, in which respiratory difficulties, such as wheeze, cough with sputum, shortness of breath and a tight chest, are the most common symptoms. AR, which may occur together with conjunctivitis, affects the supralaryngeal portion of the airways and is triggered by the nasal epithelium coming into contact with allergens, thus provoking an inflammatory response initiated by specific IgE. Patients complain of nasal discharge, pruritus, sneeze and blockage of the nose. There is a similar inflammatory pattern in both regions of the airway, if AR or asthma is chronic or when allergens are deliberately presented to the airway mucosa in a provocation test. In both conditions, there are indications of a systemic inflammatory response that may lead to eosinophilic inflammation of the entire airways. Asthma and AR are frequently found together, and AR is a strong predictor for asthma. The fact that asthma and AR can both be treated in similar fashion is also suggestive of a close similarity between the two conditions. Guidelines for management pay attention to this connection and advise assessing patients presenting with asthma for AR and vice versa. Pharmacotherapy should aim to treat both disorders simultaneously for maximum control and to reduce the number of agents needed for treatment. It is plausible that treatment guidelines may eventually suggest a goal of managing the entire respiratory system at once. Such a development would pave the way for a fully inclusive view of personalised holistic management of both the upper and lower airway.
Published: 2020

43. Effects of MACVIA-ARIA Sentinel Network for Allergic Rhinitis (MASK-Air) Mobile Phone Application on Asthma Control in Patients with Asthma

Author: Muge Gencer, Yavuz Havlucu, Jean Bousquet, Arzu Yorgancioglu, Deniz Kizilirmak, and Bilun Gemicioglu
Subjects: medicine.medical_specialty, business.industry, Mobile phone, Asthma control, Emergency medicine, medicine, In patient, medicine.disease, business, Asthma
Published: 2020

44. COVID-19 pandemic alert: time to focus on lung health-Beijing call to action for lung health promotion

Author: Tuyet Lan Le Thin, Sooronbaev Talant, Taborda-Barata Luis, Conceicao Claudia, Mohammad Yousser, Valiuis Arunas, Arzu Yorgancioglu, El Sony Asma, Cherian Varghese, M. Gaga, Harding Letitia, Teresa To, Halpin David, Bousquet Jean, Cruz Alvaro, Maghlakelidze Tamaz, Nunes Elizabete, Asthma Cen, Bennour Kazi, Williams Sian, Pigearias Bernard, Camargos Paolo, Wang Chen, Diaz Sandra Gonzales, Viegi Giovanni, Gaga Mina, Yorgancioglu Arzu, Giuseppe Troisi, Erhola Marina, Stelmach Rafael, Masjedi Muhammed Reza, Boulet Louis Philippe, Behera Digamber, Talant Sooranbaev, and Asher Innes
Subjects: Pulmonary and Respiratory Medicine, Focus (computing), Coronavirus disease 2019 (COVID-19), business.industry, media_common.quotation_subject, Editorial of GARD Section, Call to action, Promotion (rank), Beijing, Nursing, Lung health, Pandemic, Medicine, business, media_common
Published: 2020

45. ARIA��EAACI statement on asthma and COVID��19 (June 2, 2020)

Author: Tari Haahtela, Victoria Cardona, Alvaro A. Cruz, Anna Bedbrook, Ken Ohta, Wienczyslawa Czarlewski, Nikos G. Papadopoulos, Marc Humbert, Menachem Rottem, Violeta Kvedariene, Omar S. Usmani, Eric D. Bateman, Helga Kraxner, Ludger Klimek, Hubert Blain, Thomas B. Casale, Mário Morais-Almeida, Aziz Sheikh, Joaquin Sastre, Piotr Kuna, Giovanni Rolla, Nataliya Ilina, Thomas Eiwegger, Seppo Koskinen, Tomas Chivato, Torsten Zuberbier, Nicola Scichilone, De Yun Wang, Luisa Brussino, Désirée Larenas-Linnemann, Manuel Soto-Martínez, Maciej Kupczyk, Karin Hoffmann-Sommergruber, Sharon Chinthrajah, Karl Christian Bergmann, M. Gotua, Sinthia Bosnic-Anticevich, Charlotte Suppli-Ulrik, Marek L. Kowalski, Mübeccel Akdis, Bilun Gemicioglu, Petr Panzner, Giovanni Viegi, Elisabete Nunes, Jürgen Schwarze, Sanna Toppila-Salmi, Ioanna Tsiligianni, Hui Du, Wytske Fokkens, Maria Teresa Ventura, Eckard Hamelmann, Paulo Augusto Moreira Camargos, Dmitry Kudlay, Mateo Bonini, Sian Williams, Mina Gaga, Louis-Philippe Boulet, Ignacio J. Ansotegui, Teresa To, Oliver Pfaar, Ioana Agache, Giorgio Walter Canonica, João Fonseca, Leyla Namazova, K. S. Bennoor, Elena Camelia Berghea, Ya-dong Gao, Roland Buhl, David M.G. Halpin, Gabrielle L. Onorato, Nhân Pham-Thi, Todor A. Popov, Mihaela Zidarn, Stefania Nicola, Branislava Milenkovic, Robyn E O'Hehir, Kari C. Nadeau, Juan Carlos Ivancevich, Luís Taborda-Barata, Florin Mihaltan, Amir Hamzah Abdul Latiff, Rafael Stelmach, Marek Jutel, Frederico S. Regateiro, B. Pigearias, Theodor Vontetsianos, Ruby Pawankar, Mohammad R. Masjedi, Renaud Louis, Musa Khaitov, Manuel E. Soto-Quiros, Lan T. Le, H. Neffen, Yousser Mohammad, Yoshitaka Okamoto, Fanny W.S. Ko, Yehia El-Gamal, Edward F. Knol, Gary W.K. Wong, Guy Joos, Gianni Passalacqua, Jean Bousquet, Paul M. O'Byrne, Arunas Valiulis, Cezmi A. Akdis, George Christoff, Bolesław Samoliński, Claus Bachert, Vincenzo Patella, Josep M. Antó, Arzu Yorgancioglu, Michael Levin, Liam O'Mahony, Mario E. Zernotti, Erik Melén, Joaquim Mullol, Peter Valentin Tomazic, Stefano Del Giacco, Francesca Puggioni, Milan Sova, Bruce Kirenga, UAM. Departamento de Medicina, Ear, Nose and Throat, AII - Inflammatory diseases, Bousquet J., Jutel M., Akdis C.A., Klimek L., Pfaar O., Nadeau K.C., Eiwegger T., Bedbrook A., Ansotegui I.J., Anto J.M., Bachert C., Bateman E.D., Bennoor K.S., Berghea E.C., Bergmann K.-C., Blain H., Bonini M., Bosnic-Anticevich S., Boulet L.-P., Brussino L., Buhl R., Camargos P., Canonica G.W., Cardona V., Casale T., Chinthrajah S., Akdis M., Chivato T., Christoff G., Cruz A.A., Czarlewski W., Del Giacco S., Du H., El-Gamal Y., Fokkens W.J., Fonseca J.A., Gao Y., Gaga M., Gemicioglu B., Gotua M., Haahtela T., Halpin D., Hamelmann E., Hoffmann-Sommergruber K., Humbert M., Ilina N., Ivancevich J.-C., Joos G., Khaitov M., Kirenga B., Knol E.F., Ko F.W., Koskinen S., Kowalski M.L., Kraxner H., Kudlay D., Kuna P., Kupczyk M., Kvedariene V., Abdul Latiff A.H., Le L.T., Levin M., Larenas-Linnemann D., Louis R., Masjedi M.R., Melen E., Mihaltan F., Milenkovic B., Mohammad Y., Morais-Almeida M., Mullol J., Namazova L., Neffen H., Nunes E., O'Byrne P., O'Hehir R., O'Mahony L., Ohta K., Okamoto Y., Onorato G.L., Panzner P., Papadopoulos N.G., Passalacqua G., Patella V., Pawankar R., Pham-Thi N., Pigearias B., Popov T.A., Puggioni F., Regateiro F.S., Rolla G., Rottem M., Samolinski B., Sastre J., Schwarze J., Sheikh A., Scichilone N., Soto-Quiros M., Soto-Martinez M., Sova M., Nicola S., Stelmach R., Suppli-Ulrik C., Taborda-Barata L., To T., Tomazic P.-V., Toppila-Salmi S., Tsiligianni I., Usmani O., Valiulis A., Ventura M.T., Viegi G., Vontetsianos T., Wang D.Y., Williams S., Wong G.W.K., Yorgancioglu A., Zernotti M., Zidarn M., Zuberbier T., and Agache I.
Subjects: 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Allergy, Statement (logic), Medicina, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), viruses, Immunology, Settore MED/10 - Malattie Dell'Apparato Respiratorio, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, astma, Medicine and Health Sciences, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Letters to the Editor, Letter to the Editor, udc:616.2, Asthma, Coronavirus, Science & Technology, business.industry, SARS-CoV-2, virus diseases, COVID-19, asthma, medicine.disease, Virology, 3. Good health, 030228 respiratory system, covid-19, 1107 Immunology, Angiotensin-Converting Enzyme 2, business, ARIA-EAACI, Life Sciences & Biomedicine, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract: Artículo con numerosos autores sólo se mencionan el primero y el de la UAM, Open access funding enabled and organized by Projekt DEAL
Published: 2020
Full Text: View/download PDF

46. Pregnancy Outcomes of Patients with Asthma under Omalizumab Treatment: Case Report of a Country based Experience on 22 Pregnancies and 23 Infants

Author: Gül Karakaya, Ipek Kivilcim Oguzulgen, Dane Ediger, Yavuz Havlucu, Arzu Yorgancioglu, Arzu Didem Yalcin, Metin Keren, Sevim Bavbek, Zeynep Ferhan Ozseker, Bilun Gemicioglu, and Levent Özdemir
Subjects: Pregnancy, Pediatrics, medicine.medical_specialty, Exacerbation, business.industry, Breastfeeding, Infant exposure, General Medicine, Disease, Omalizumab, medicine.disease, Low birth weight, medicine, medicine.symptom, business, Asthma, medicine.drug
Abstract: A prospective multicenter study reported safety of omalizumab in pregnant asthmatics. However, real life data about the topic is scarce. Therefore, we aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our county. Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their demographic features, disease- and therapy-related parameters, and the health of their infants. 20 pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 second (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each, and 17 to one infant each. Infant exposure to omalizumab was only one dose (300 mg omalizumab) for the twins, the first trimester for one infant, second and third trimester for four infants, and during all pregnancy and breastfeeding periods for 16 infants. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.
Published: 2020

47. Protocol for the EARCO Registry

Author: Ravi Mahadeva, Christian F. Clarenbach, Ilaria Ferrarotti, Aleksandra Ilic, Jan Stolk, Angelo Corsico, Robert A. Stockley, Alvils Krams, Malcolm Kohler, Jean-François Mornex, Maria Sucena, Alice M Turner, Eava Piitulainen, Cristina Esquinas, Beatriz Lara, Yavor Ivanov, Marc Miravitlles, Caroline Gouder, Gerry McElvaney, Karen O'Hara, Arzu Yorgancioglu, Ana Hećimović, Ana Zaharie, Robert Bals, Alan Altraja, Ruxandra Ulmeanu, Sabina Janciauskiene, Luciano Corda, Niels Seersholm, Karin Schmid-Scherzer, Jan Chlumsky, Timm Greulich, Wim Janssens, Marion Wilkens, Joanna Chorostowska-Wynimko, Miriam Barrecheguren, Hanan A Tanash, David G. Parr, University of Zurich, Greulich, Timm [0000-0002-2368-3014], Altraja, Alan [0000-0001-7798-9871], Bals, Robert [0000-0002-1472-9535], Chorostowska-Wynimko, Joanna [0000-0003-1743-2961], Clarenbach, Christian [0000-0003-2158-2321], Ferrarotti, Ilaria [0000-0003-4892-4192], Janssens, Wim [0000-0003-1830-2982], Lara, Beatriz [0000-0003-0090-8206], Turner, Alice [0000-0002-5947-3254], Miravitlles, Marc [0000-0002-9850-9520], Apollo - University of Cambridge Repository, Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and European Respiratory SocietyKamadapH PharmaCSL BehringGrifols
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Chronic Obstructive Pulmonary Disease, Population, MEDLINE, lcsh:Medicine, 32 Biomedical and Clinical Sciences, 610 Medicine & health, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 03 medical and health sciences, Liver disease, Study Protocol, 0302 clinical medicine, Rare Diseases, Clinical Research, medicine, Genetics, 030212 general & internal medicine, Intensive care medicine, education, 3202 Clinical Sciences, Lung, Protocol (science), Emphysema, education.field_of_study, business.industry, Prevention, lcsh:R, medicine.disease, 3. Good health, Natural history, Clinical research, 030228 respiratory system, Observational study, 10178 Clinic for Pneumology, business, Cohort study
Abstract: Rationale and objectives Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that leads to an increased risk of emphysema and liver disease. Despite extensive investigation, there remain unanswered questions concerning the natural history, pathophysiology, genetics and the prognosis of the lung disease in association with AATD. The European Alpha-1 Clinical Research Collaboration (EARCO) is designed to bring together researchers from European countries and to create a standardised database for the follow-up of patients with AATD. Study design and population The EARCO Registry is a non-interventional, multicentre, pan-European, longitudinal observational cohort study enrolling patients with AATD. Data will be collected prospectively without interference/modification of patient's management by the study team. The major inclusion criterion is diagnosed severe AATD, defined by an AAT serum level, The EARCO Registry is a non-interventional, multicentre, pan-European, longitudinal observational cohort study enrolling patients with AATD to elucidate the natural history, pathophysiology, genetics and prognosis of this condition http://bit.ly/369ScCc
Published: 2020

48. A global respiratory perspective on the COVID-19 pandemic: Commentary and action proposals

Author: Tamaz Maghlakelidze, Alvaro A. Cruz, Marina Erhola, Sandra Diaz, Luís Taborda-Barata, Mina Gaga, Elizabete Nunes, Rafael Stelmach, Giovanni Viegi, Digambar Behera, B. Pigearias, Sian Williams, Yousser Mohammad, Innes Asher, Paulo Augusto Moreira Camargos, Arzu Yorgancioglu, Ioanna Tsiligianni, Jean Bousquet, K. S. Bennoor, Mohammad Reza Masjedi, Asma El-Sony, Cláudia Conceição, Letitia Harding, Teresa To, Talant Sooronbaev, Louis-Philippe Boulet, Arunas Valiulis, Chen Wang, Le Thi Tuyet Lan, and David M.G. Halpin
Subjects: Pulmonary and Respiratory Medicine, Coronavirus disease 2019 (COVID-19), Health care provider, COVID19, Pneumonia, Viral, MEDLINE, infectious diseases, 03 medical and health sciences, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Nursing, Pandemic, Medicine, Humans, 030212 general & internal medicine, Pandemics, Community level, Health management system, business.industry, Perspective (graphical), COVID-19, COVID-19 pandemic, global respiratory perspective, COPD, Asthma, Editorial, 030228 respiratory system, Action (philosophy), business, Coronavirus Infections
Abstract: To date, the COVID-19 pandemic has affected over five million individuals worldwide and killed hundreds of thousands individuals of all ages and ethnicities. People with chronic respiratory diseases like asthma and COPD (Chronic Obstructive Pulmonary Disease) are particularly vulnerable to respiratory infections. In this document, we, an international group of respiratory health care providers and researchers, summarised our hands-on experience and lessons learned from combating COVID-19 according to three perspectives: 1) patient level: interactions with health care providers; 2) health care provider level: real-time experience sharing; and 3) community level: environmental impact, air pollution. Our proposed actions and implementations are practical and feasible and may foster deeper thoughts and considerations into how to move forward in managing the heavy respiratory burden in times of COVID-19., This paper offers practical and feasible actions to be implemented at patient, health care provider and community level to combat COVID-19 while attending, maintaining and strengthening ongoing health management in people with lung diseases.
Published: 2020

49. Does asthma control as assessed by the asthma control test reflect airway inflammation?

Author: Pinar Celik, Mine Bora, Aylin Ozgen Alpaydin, Arzu Yorgancioglu, Aysin Sakar Coskun, Gizem Akkas, and Aydin Isisag
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Pulmonary function testing, Internal medicine, Medicine, Eosinophilia, Outpatient clinic, Asthma, lcsh:RC705-779, business.industry, asthma control test, lcsh:Diseases of the respiratory system, methacholine bronchial provocation test, respiratory system, medicine.disease, Neutrophilia, respiratory tract diseases, Cardiothoracic surgery, Exhaled nitric oxide, Physical therapy, Airway eosinophilia, exhaled nitric oxide, Methacholine, Original Article, medicine.symptom, business, medicine.drug
Abstract: Background and aims The treatment of asthmatic patients is particularly focused on the control of symptoms as well as functional and inflammatory parameters. In our study, we investigated the relationship between the asthma control test (ACT) which evaluates symptoms and airway inflammation and functional parameters. Materials and methods Stable asthmatic patients admitted to our pulmonary outpatient clinic were enrolled in the study consecutively and underwent the ACT, pulmonary function tests and methacholine bronchial provocation test (MBPT). Additionally, fractional exhaled nitric oxide level (FeNO) and induced sputum cell distribution were assessed. All these parameters were re-evaluated at the third month after adjusting medications of the patients according to baseline ACT scores. Results Of the 101 patients screened, we analyzed 83 who proceeded to the follow up visit. At the baseline visit, 8 were totally controlled, 36 partially controlled and 39 uncontrolled according to ACT. At the follow up visit, 10 were totally controlled, 39 partially controlled and 34 uncontrolled. Comparison of the two visits in terms of all parameters revealed significant reductions only in the percentages of patients with MBPT positivity (p = 0.029) and FeNO levels > 20 ppb (p = 0.025) at follow up. The percentages of patients with FeNO > 20 ppb, MBPT positivity, induced sputum eosinophilia or induced sputum neutrophilia did not show significant differences between totally controlled, partially controlled and uncontrolled groups at both baseline and follow up visits. Conclusion Although the ACT scores did not show significant correlations with the airway inflammation parameters tested in this study, a marked reduction in the percentage of patients with MBPT positivity and FeNO > 20 ppb at follow up may suggest the importance of the control concept in the management of asthma.
Published: 2019

50. Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?

Author: Désirée Larenas-Linnemann, Fulvio Braido, Paolo Maria Matricardi, Wienczyslawa Czarlewski, Alvaro A. Cruz, Sanna Toppila-Salmi, Oliver Pfaar, Dana Wallace, Torsten Zuberbier, Pascal Demoly, Olga Lourenço, Anna Bedbrook, Daniel Laune, Nhân Pham-Thi, Violeta Kvedariene, Piotr Kuna, Marina Erhola, Ignacio J. Ansotegui, Annabelle Bédard, V. Cardona, Salvadore Tripodi, Maria Teresa Ventura, João Fonseca, Nikos Papadopoulos, Michiel van Eerd, Maddalena Illario, Sylvie Arnavielhe, Juan Carlos Ivancevich, Peter Hellings, Gabrielle L. Onorato, Sinthia Bosnic-Anticevich, Ludger Klimek, Teresa To, Jean Bousquet, Arzu Yorgancioglu, W. J. Fokkens, Peter Valentin Tomazic, Xavier Basagaña, Erik Melén, Josep M. Antó, Arunas Valiulis, Matteo Bonini, Claus Bachert, Vesa Jormanainen, Aziz Sheikh, Stephanie Dramburg, Rachel Tan, Joaquim Mullol, Tari Haahtela, Eve Mathieu-Dupas, Govert De Vries, Ear, Nose and Throat, AII - Inflammatory diseases, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hospital Quiròn Bizkaia Erandio, CIBER de Epidemiología y Salud Pública (CIBERESP), Universitat Pompeu Fabra [Barcelona] (UPF), KYomed INNOV, Ghent University Hospital, Università cattolica del Sacro Cuore [Roma] (Unicatt), Imperial College London, UNSW Faculty of Medicine [Sydney], University of New South Wales [Sydney] (UNSW), University of Genoa (UNIGE), Vall d'Hebron University Hospital [Barcelona], UCB Pharma, Colombes, Universidade Federal da Bahia (UFBA), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Peercode (Développement de l'application) Oudenhof 4c 4191 NW Geldermalsen, Pays-Bas., Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), National Institute for Health and Welfare [Helsinki], European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), VU University Medical Center [Amsterdam], Faculdade de Medicina da Universidade do Porto (FMUP), Universidade do Porto, University of Helsinki, University Hospitals Leuven [Leuven], University of Amsterdam [Amsterdam] (UvA), 'Federico II' University of Naples Medical School, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Medical University of Łódź (MUL), Vilnius University [Vilnius], Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Clínica de Alergia- Asma y Pediatría, Hospital Medica Sur, University of Beira Interior [Portugal] (UBI), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Transverse group for research in primary care [Barcelona], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Manchester [Manchester], University of Athens Medical School [Athens], Philipps University of Marburg, Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris], University of Edinburgh, The University of Sydney, Sidkkids Hospital and Institute of Health Policy (Management and Evaluation), Medical University Graz, Policlinico Casilino (Ospedale Policlinico Casilino), Nova Southeastern University (NSU), University of Bari Aldo Moro (UNIBA), Manisa Celal Bayar University, Humboldt-Universität zu Berlin, Bousquet, J., Ansotegui, I. J., Anto, J. M., Arnavielhe, S., Bachert, C., Basagana, X., Bedard, A., Bedbrook, A., Bonini, M., Bosnic-Anticevich, S., Braido, F., Cardona, V., Czarlewski, W., Cruz, A. A., Demoly, P., De Vries, G., Dramburg, S., Mathieu-Dupas, E., Erhola, M., Fokkens, W. J., Fonseca, J. A., Haahtela, T., Hellings, P. W., Illario, M., Ivancevich, J. C., Jormanainen, V., Klimek, L., Kuna, P., Kvedariene, V., Laune, D., Larenas-Linnemann, D., Lourenco, O., Onorato, G. L., Matricardi, P. M., Melen, E., Mullol, J., Papadopoulos, N. G., Pfaar, O., Pham-Thi, N., Sheikh, A., Tan, R., To, T., Tomazic, P. V., Toppila-Salmi, S., Tripodi, S., Wallace, D., Valiulis, A., van Eerd, M., Ventura, M. T., Yorgancioglu, A., Zuberbier, T., CCSD, Accord Elsevier, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Hospital Quirónsalud Bizkaia [Bilbao], Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), Università degli studi di Genova = University of Genoa (UniGe), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Universidade do Porto = University of Porto, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Philipps Universität Marburg = Philipps University of Marburg, Institut Pasteur [Paris] (IP), Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Humboldt University Of Berlin, uBibliorum, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University Hospital, Montpellier, France, MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, VIMA, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, Montigny le Bretonneux, France, Euforea, Brussels, Belgium, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Department of Dermatology and Allergy, Berlin Institute of Health, Comprehensive Allergy Center, Berlin, Germany, Department of Allergy and Immunology, Hospital Quirónsalud Bizkaia, Erandio, Spain, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, Hospital del Mar Research Institute, Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, KYomed INNOV, Montpellier, France, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, UOC Pneumologia, Istituto di Medicina Interna, F Policlinico Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, National Heart and Lung Institute, Royal Brompton Hospital & Imperial College London, London, United Kingdom, Woolcock Institute of Medical Research, University of Sydney, Glebe, NSW, Australia, Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia, Department of Internal Medicine (DiMI), University of Genoa, Genova, Italy, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain, Medical Consulting Czarlewski, Levallois, France, ProAR—Nucleo de Excelencia em Asma, Federal University of Bahia, Salvador, Brazil, WHO GARD Planning Group, Salvador, Brazil, Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France, Equipe EPAR—IPLESP, Sorbonne Université, Paris, France, Peercode BV, Geldermalsen, Netherlands, Department of Pediatric Pulmonology, Immunology and Intensive Care Medicine, Charité—University Medicine Berlin, Berlin, Germany, National Institute for Health and Welfare, Helsinki, Finland, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda, Porto, Portugal, Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET), Naples, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Institute of Clinical Medicine, Clinic of Chest Diseases and Allergology, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Faculty of Health Sciences and CICS—UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal, AG Molecular Allergology and Immunomodulation, Department of Pediatric Pneumology and Immunology, Charité Medical University, Berlin, Germany, E. Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital 'P&A Kyriakou', University of Athens, Athens, Greece, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität Marburg, Marburg, Germany, Allergy Department, Pasteur Institute, Paris, France, The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Sidkkids Hospital and Institute of Health Policy, Management and Evaluation, Toronto, Ontario, Canada, Department of General ORL, H&NS, Medical University of Graz, Graz, Austria, Allergy Unit, Policlinico Casilino, Rome, Italy, Nova Southeastern University, Fort Lauderdale, Fla, United States, Institute of Clinical Medicine, Clinic of Children's Diseases, Vilnius University, Vilnius, Lithuania, Institute of Health Sciences, Department of Public Health, Vilnius University, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, Charité—Universitätsmedizin Berlin, Berlin, Germany, Corporate member of Freie Universität Berlin, Humboldt-Uniersität zu Berlin, and Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and Allergy, Berlin, Germany, Member of GA2LEN, Berlin, Germany, and Centre Médical de l'Institut Pasteur
Subjects: SENTINEL NETWORK, Allergy, IMPACT, [SDV]Life Sciences [q-bio], digital transformation of health, 0302 clinical medicine, Risk Factors, Immunology and Allergy, Medicine, 030212 general & internal medicine, MASK-RHINITIS, mHealth, Rhiniti, media_common, Rhinitis, SMARTPHONE, WORK PRODUCTIVITY, Mobile Applications, Telemedicine, 3. Good health, [SDV] Life Sciences [q-bio], Europe, Digital transformation of health, Phenotype, General Data Protection Regulation, DISEASE SEVERITY, Smartphone, Life Sciences & Biomedicine, PHARMACOLOGICAL-TREATMENT, Human, Apps, MASK, Mobile technology, digital transformation of health, mHealth, rhinitis, MASK, Immunology, Internet privacy, Mobile Application, [INFO] Computer Science [cs], Clinical decision support system, MACVIA-ARIA, 03 medical and health sciences, ADHERENCE, rhinitis, Mobile technology, media_common.cataloged_instance, Humans, [INFO]Computer Science [cs], European union, App -MASK, Science & Technology, business.industry, Risk Factor, Digital transformation, Usability, Apps, Rhinitis, Allergic, Health care delivery, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, ASTHMA, business, App, Delivery of Health Care
Abstract: Smart devices and Internet-based applications (apps) are largely used in allergic rhinitis and may help to address some unmet needs. However, these new tools need to first of all be tested for privacy rules, acceptability, usability, and cost-effectiveness. Second, they should be evaluated in the frame of the digital transformation of health, their impact on health care delivery, and health outcomes. This review (1) summarizes some existing mobile health apps for allergic rhinitis and reviews those in which testing has been published, (2) discusses apps that include risk factors of allergic rhinitis, (3) examines the impact of mobile health apps in phenotype discovery, (4) provides real-world evidence for care pathways, and finally (5) discusses mobile health tools enabling the digital transformation of health and care, empowering citizens, and building a healthier society. ispartof: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE vol:7 issue:8 pages:2511-2523 ispartof: location:United States status: published
Published: 2019

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Category

Publication Type

Journal

Database

Publisher

107 results on '"Arzu Yorgancioglu"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources